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Dopamine (DA) is critically important in numerous aspects of normal central nervous system 
(CNS) function and the etiology of several CNS disorders, including Parkinson’s disease, 
substance abuse, and attention deficit hyperactive disorder.  The diversity of DA function and 
dysfunction means an understanding of the mechanisms that control extracellular DA 
concentrations and their spatiotemporal dynamics is highly significant.  Such mechanisms have 
been extensively studied in the subregions of the striatum, e.g. the dorsal striatum and nucleus 
accumbens that play central roles in motor control and reword-addiction. 
To measure DA concentration changes in extracellular space, two techniques have been heavily 
used in the in vivo studies: microdialysis and electrochemistry.  Microdialysis sampling of the 
brain is straightforward and has numerous applications.  But implanting microdialysis probe into 
brain tissue causes a penetration injury.  Thus, the probe samples injured tissue.  In Chapter I, we 
used dexamethasone, a potent anti-inflammatory and immunosuppressant drug, to mitigate the 
effect of the penetration injury and examined its effects using fluorescence imaging and no-net-
flux measurement.  We conclude that dexamethasone is highly effective at suppressing gliosis 
and ischemia but is limited in its neuroprotective activity.  
In vivo electrochemistry, using carbon fiber microelectrodes with single-digit micrometer 
diameter and 100-400 micrometer in detecting length coupled with fast-scan cyclic voltammetry, 
offers high spatial and temporal resolution with minimal tissue damage.  Taking these 
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advantages, our group has demonstrated that DA in the rat dorsal striatum is organized as a 
patchwork of domains that show distinct DA kinetics.  In Chapter II, we demonstrated that a 
patchwork of domains exists in the rat nucleus accumbens core (NAcc), but shows substantial 
differences between the NAcc domains and those of the dorsal striatum.  There are no signs of 
short-term plasticity during multiple consecutive stimuli nor a domain-dependent autoinhibitory 
tone in NAcc.  In Chapter III, we examine the domain-dependent actions of nomifensine, a 
competitive DA transport inhibitor, in NAcc and demonstrated that it preferentially enhance 
evoked DA overflow in slow domains compared with fast domains.  We quantified the apparent 
KM of DA clearance and concluded that nomifensine preferentially increases the apparent KM in 
NAcc compared with dorsal striatum. 
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  1 
INTRODUCTION 
Dopamine (DA) in central neuronal systems (CNS) plays an important role in many of body’s 
vital functions, such as planning and modulation of pathways, reward, mood regulation and 
attention (Schultz 2007).  And dysfunction in dopaminergic systems has been found involving in 
many pathologies, including Parkinson’s disease, schizophrenia, attention deficit hyperactivity 
disorder and substance abuse (Grace 1991, Swanson 2000, Lotharius & Brundin 2002).  
However, the mechanisms of dopamine signaling in CNS are not well defined in both functions 
and dysfunctions.  Take attention deficit hyperactivity disorder (ADHD) for instance.  ADHD is 
the most commonly studied and diagnosed psychiatric disorder in children, which has three 
subtypes: predominantly hyperactive-impulsive, predominantly inattentive and combined 
hyperactive-impulsive and inattentive (Porcerelli et al. 2011).  According to the current 
dopamine models, hyperactive is associated with elevated dopamine levels (Grace 2000).  
However, in practice, ADHD symptoms in all subtypes can be alleviated with the treatment of 
methylphenidate, a reuptake inhibitor of dopamine transporter, which increases dopamine levels 
(Wender et al. 2011).  So, how did further increasing dopamine level in patients with 
predominantly hyperactive-impulsive subtype relieve the symptoms, if high dopamine level is 
the cause?  The paradox here is a matter of longstanding interest. 
Dopamine neurological system is a network of neurons that communicate through the 
released dopamine molecules in extracellular space as neurotransmitters.  In central neuronal 
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systems, cell bodies of dopamine neurons are mainly located in two areas: substantial nigra and 
ventral tegmental area.  Their axons are crossing the medial forebrain bundle and project their 
terminals in striatum and nucleus accumbens at high density.  Dopamine molecules packed in 
vesicles inside pre-synaptic terminals are released into the synaptic cleft, which is approximately 
300 nm in length and 15 nm in width, and quickly diffused into extracellular space (Garris & 
Wightman 1994).  The release has been further regulated by two families of dopamine 
autoreceptors, D1-like and D2-like, which primarily located outside cleft (Garris & Wightman 
1994, Sesack et al. 1994).  In extracellular space, released dopamine molecules can activates pre-
synaptic receptors until removed back into terminals by the dopamine transporters (DAT).  Thus, 
the spatiotemporal dynamics of DA’s extracellular concentration, and therefore the extent and 
duration of DA receptor stimulation, are intricately determined by the kinetics of DA release and 
clearance as well as the mass transport of DA through the extracellular space (Wightman et al., 
1988; Garris et al., 1994; Cragg & Rice, 2004; Taylor et al., 2012; Taylor et al., 2013). 
In order to measure dopamine concentration changes in extracellular space, two 
techniques have been heavily used in the in vivo studies: microdialysis and electrochemistry.  
Microdialysis is a widely and frequently used sampling technique (Chaurasia et al. 2007).  Small 
molecules such as dopamine and serotonin are recovered from extracellular space in central 
neuron system by diffusing into a perfusate through a semi-permeable membrane on a 
microdialysis probe.  Samples of the dialysate are usually analyzed by HPLC or capillary 
electrophoresis coupled with a variety of detection methods.  The benefit of microdialysis is that 
dialysate is carrying the analyte out of the living system so it can be easily analyzed with 
separation and detection steps that provide extremely high selectivity.  For in vivo 
electrochemistry, on the order hand, analyte separation and detection processes are self-
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contained and in situ, and chemical identification is relied on voltammograms (Wightman et al. 
1988b).  Although in vivo electrochemical technique is limited in chemical selectivity comparing 
to microdialysis, it can provide information that are not presently accessible by microdialysis or 
any other measurements, as it offers high spatial and temporal resolution (Borland & Michael 
2007).  Carbon fibers with single-digit micrometer diameter are constructed as chemical 
microsensors with 100 to 400 μm in detecting length, which are more than then thousand times 
smaller than typical microdialysis probes in volume.  One of the advantages of their small 
dimensions is that minimal damage can be achieved when implanting microsensors into living 
brain tissues, which ensures the information collected are not biased by presence of the sensor 
(Peters et al. 2004, Jaquins-Gerstl & Michael 2009).  Another advantage is that minimal damage 
will allow the carbon fiber electrode to be placed within micrometer distance of normal neuronal 
terminals (Venton et al. 2003, Peters et al. 2004, Taylor et al. 2012).  So it can reveal the highly 
localized activities such as heterogeneity of evoked dopamine release (Garris et al. 1994b, 
Moquin & Michael 2009, Taylor et al. 2012) and evaluate kinetics of dopamine transporter 
(Garris et al. 1994a, Wu et al. 2001, Wu et al. 2002, Michael et al. 2005, Shu et al. 2013, Shu et 
al. 2014, Walters et al. 2014) suffering little diffusional distortion.  The high temporal resolution 
can also benefit electrochemical recordings on detecting dopamine concentration change within 
subsecond time frame: monitoring dopamine release and clearance triggered by brief electrical 
stimulation such as 12 pulses stimulus or even recording the non-evoked dopamine transients in 
the brain of freely moving animals (Robinson et al. 2002, Robinson & Wightman 2004, 
Wightman et al. 2007). None of them above are visible in the microdialysis because of the 
temporal blurring associated with diffusion across the dialysis membrane and spatial averaging 
associated with large sampling area.  Thus, it is clear that high spatial and temporal resolution of 
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electrochemical techniques can provide unique information about the characteristics of dopamine 
systems in the living brain tissue. 
In Chapter I, we examined and mitigated the penetration injury associated with brain 
microdialysis.  Microdialysis sampling of the brain is an analytical technique with numerous 
applications in neuroscience and the neurointensive care of brain-injured human patients.  Even 
so, implanting microdialysis probes into brain tissue causes a penetration injury that triggers 
gliosis (the activation and proliferation of glial cells) and ischemia (the interruption of blood 
flow).  Thus, the probe samples injured tissue.  Mitigating the effects of the penetration injury 
might refine the technique.  The synthetic glucocorticoid, dexamethasone, is a potent anti-
inflammatory and immunosuppressant substance.  We performed microdialysis in the rat brain 
for 5 days, with and without dexamethasone in the perfusion fluid (10 μM for the first 24 hrs and 
2 μM thereafter).  On the 1st and 4th day of the perfusion, we performed dopamine no-net-flux 
measurements.  On the 5th day, we sectioned and stained the brain tissue and examined it by 
fluorescence microscopy.  Although dexamethasone profoundly inhibited gliosis and ischemia 
around the probe tracks it had only modest effects on dopamine no-net-flux results.  These 
findings show that dexamethasone is highly effective at suppressing gliosis and ischemia but is 
limited in its neuroprotective activity. 
In Chapter II, we addressed the hypothesis that a domain patchwork might also exist in 
the nucleus accumbens core (NAcc), a DA terminal field involved deeply in reward processing 
and the mechanisms underlying substance abuse.  The dopamine (DA) terminal field in rat dorsal 
striatum is organized as a patchwork of domains that exhibit distinct DA kinetics.  The rate and 
short-term plasticity of evoked DA release, the rate of DA clearance, and the actions of several 
dopaminergic drugs are all domain-dependent.  The patchwork arises in part from local 
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variations in DA’s basal extracellular concentration, which establishes an autoinhibitory tone in 
slow but not fast domains.  DA recordings in the NAcc by fast-scan voltammetry during 
electrical stimulation of the medial forebrain bundle confirm that the NAcc contains a patchwork 
of fast and slow domains exhibiting significantly different rates of evoked DA release and DA 
clearance.  Moreover, the NAcc domains are substantially different from those in the dorsal 
striatum.  There are no signs in the NAcc of short-term plasticity of DA release during multiple 
consecutive stimuli and no signs of a domain-dependent autoinhibitory tone.  Thus, the NAcc 
domains are distinct from each other and from the domains of the dorsal striatum. 
In Chapter III, we used fast-scan cyclic voltammetry recordings of electrically evoked 
DA overflow to test the hypothesis that nomifensine might exhibit domain-dependent actions 
within the NAcc, as we previously found to be the case within the DS.  Within the NAcc, 
nomifensine preferentially enhanced evoked dopamine overflow in the slow compared to the fast 
domains.  To seek a kinetic explanation for nomifensine’s selective actions, we quantified the 
apparent KM of DA clearance by numerically evaluating the derivative of the descending phase 
of the DA signal after the end of the stimulus.  For comparison, we likewise quantified apparent 
KM in the domains of the DS.  As expected because it is a competitive inhibitor, nomifensine 
significantly increased the apparent KM in both the fast and slow domains of both the NAcc and 
DS.  However, our analysis also leads to the novel finding that nomifensine preferentially 
increases the apparent KM in the NAcc compared to the DS: apparent KM increased by ~500% in 
the NAcc and ~200% in the DS. 
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CHAPTER I.  EFFECT OF DEXAMETHASONE ON GLIOSIS, ISCHEMIA, AND 
DOPAMINE EXTRACTION DURING MICRODIALYSIS SAMPLING IN BRAIN 
TISSUE 
Adapted with revision from Andrea Jaquins-Gerstl, Zhan Shu, Jing Zhang, Yansheng Liu, 
Stephen G. Weber, and Adrian C. Michael, (2011) Analytical Chemistry, 83, 7662-7667.   
Zhan Shu’s contribution to this published article is the dopamine no-net-flux 
microdialysis measurement, mainly presented as Figure I.8 and Table 1 in this chapter. 
A. INTRODUCTION 
The significance of brain microdialysis as an analytical technique in neuroscience is well-
established and its application as a tool for the neurointensive care of brain-injured human 
patients continues to be explored (Dreier et al., 2000; Meixensberger et al., 2001; Sakowitz et al., 
2001; Bosche et al., 2003; Dreier et al., 2006; Sakowitz et al., 2007; Fabricius et al., 2008; 
Schlenk et al., 2008; Nordstrom, 2009; Feuerstein. et al., 2010).  The power of microdialysis is 
attributable to its several beneficial attributes: the dialysate samples contain a plethora of 
interesting and important small molecules (Westerink & Cremers, 2007; Perry et al., 2009)  (for 
an extensive review see Westerink and Cremers, 2007), the technique is relatively simple to 
perform and compatible with the constraints of intensive care, the probes are commercially 
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available or easily built in-house, and the dialysis process prepares the samples for direct, often 
times on-line, analysis by a broad array of techniques, such as HLPC, CE, and MS.  
Microdialysis has contributed significantly to the understanding of normal brain function, the 
pathology of brain disorders and injuries, and the actions of neuroactive drugs, both therapeutic 
and illicit (Benveniste & Diemer, 1987; Benveniste et al., 1989; Bradberry et al., 1993; 
Bradberry et al., 2000; Rittenhouse & Pollack, 2000; Berger et al., 2002; Sarrafzadeh et al., 
2002; Parkin et al., 2005; Sakowitz & Unterberg, 2006; Hashemi et al., 2009). 
Although microdialysis provides valuable insights into brain chemistry, implanting the 
probes causes a penetration injury to the brain tissue (Clapp-Lilly et al., 1999; Zhou et al., 2002; 
Mitala et al., 2008; Hascup et al., 2009; Jaquins-Gerstl & Michael, 2009) that triggers gliosis (the 
activation and proliferation of glial cells) (Zhou et al., 2002; Mitala et al., 2008; Stroncek & 
Reichert, 2008; Jaquins-Gerstl & Michael, 2009) and ischemia (interruption of blood flow).  
Consequently, the tissue sampled by the probe is perturbed from its normal state (Stroncek & 
Reichert, 2008).  Understanding, and possibly mitigating, the effects of the penetration injury 
could be a path to enhancing the technique, refining its accuracy and precision, extending the 
viable microdialysis sampling time window, and enabling deeper insights into the neurochemical 
aspects of brain function.  Given that many neurological disorders, while treatable, are neither 
preventable nor curable and that the therapies for brain trauma remain limited, enhancing the 
chemical information output from brain microdialysis procedures stands to be highly significant. 
In the present study, we examined the effect of dexamethasone on the probe-induced 
penetration injury of the rat brain.  Dexamethasone is a synthetic, highly potent glucocorticoid 
with anti-inflammatory and immunosuppressant activity.  Several studies have demonstrated that 
gliosis at brain implants is inhibited by dexamethasone-releasing coatings (Shain et al., 2003; 
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Spataro et al., 2005; Zhong & Bellamkonda, 2007).  Furthermore, Stenken’s group recently 
reported that dexamethasone inhibits the immune response to subcutaneous microdialysis probes 
(Mou et al., 2011).  We performed microdialysis in the rat brain for 5 days with and without 
dexamethasone in the perfusion fluid.  On the 1st and 4th day of the perfusion we performed 
dopamine no-net-flux measurements and at the end of the perfusion we sectioned, stained, and 
examined the brain tissue by fluorescence microscopy to assess gliosis and ischemia.  
B. MATERIALS AND METHODS 
1. Reagents 
All reagents were used as-received from the indicated supplier.  All solutions were prepared in 
ultrapure water (Nanopure, Barnstead Inc, Dubuque, IA) and filtered with Iso-Disc TM filters, 
(N-25-2 Nylon 25mm x 0.2μm, Supelco, Bellefonte; PA).  Bovine serum albumin (BSA), 
paraformaldehyde, polyvinyl alcohol, glycerol, 1,4-diazabicyclo [2.2.2] octane (DABCO), 
Triton-X 100, dopamine (DA) and ascorbic acid were from Sigma (St. Louis; MO); 2-
methybutane was from Alfa Aesar (Ward Hill, MA); fluorescent beads were from Molecular 
Probes (0.1 μm diameter, FluoSpheres® carboxylate-modified polystyrene microspheres 
suspended (2% solids) in water with 2 mM sodium azide; Eugene, OR); primary antibody for 
glial fibrillary acidic protein (GFAP) in 0.5% BSA was from BD Biosciences Pharmingen (San 
Diego, CA); secondary antibody (goat anti-mouse IgG, CY3 in 0.5% BSA) was from Jackson 
Immunoresearch (West Grove, PA); isoflurane was from Halocarbon Products Corporation 
(North Augusta, SC); dexamethasone sodium phosphate (9-fluoro-11β,17,21-trihydroxy-16α-
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methylpregna-1,4-diene-3,20-dione-21-(dihydrogen phosphate) disodium salt, 20mg/5ml, 
American Regent Incorporated, Shirley, NY) was purchased from the University of Pittsburgh 
Presbyterian Hospital Pharmacy.  All other salts and reagents were from Fisher Scientific 
(Pittsburgh, PA).  Phosphate buffered saline (PBS) contained 155 mM NaCl and 100 mM 
phosphate adjusted to pH 7.4.  Artificial cerebrospinal fluid (aCSF) contained 144 mM Na+, 1.2 
mM Ca2+, 2.7 mM K+, 152 mM Cl-, 1.0 mM Mg2+, and 2.0 M PO43- and was adjusted to pH 7.4. 
2. Animals and surgical procedures 
All procedures involving animals were approved by the Institutional Animal Care and Use 
Committee of the University of Pittsburgh.  Male Sprague-Dawley rats (Hilltop; Scottsdale, PA) 
were anesthetized with isoflurane and wrapped in a 37 °C homoeothermic blanket (EKEG 
Electronics; Vancouver, BC, Canada) during an aseptic stereotaxic surgical procedure to position 
a guide cannula (MD-2251, Bioanalytical Systems, Inc. (BASi), West Lafayette, IN) over the 
striatum.  The guide cannula was anchored in place with bone screws and acrylic cement and 
animals were given four days for post-operative recovery before experiments continued. All 
animals regained or exceeded their pre-surgical body weight by the end of the post-operative 
recovery period. 
3. Microdialysis procedures 
Prior to use, microdialysis probes (BASi MD-2204) were sterilized with ethylene oxide and 
flushed for 1 hr with aCSF. The probes were connected via FEP tubing (MF-5164, BASi) to a 
1.0 ml gas-tight syringe (Hamilton).  Rats were re-anesthetized briefly with isoflurane and 
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returned to the stereotax while the stereotaxic carrier was used to slowly (~30 min) lower the 
probes through the guide cannula and into the striatum.  The probes were perfused with aCSF at 
a flow rate of 0.610 µL/min for 5 days by means of a syringe pump (Harvard Apparatus).  In one 
group of rats, the probes were perfused with plain aCSF.  In a second group of rats, the aCSF 
contained dexamethasone.  The dexamethasone concentration was 10 μM for the first 24 hrs of 
the perfusion and 2 μM for the remainder of the experiment: preliminary experiments showed 
that continued perfusion with 10-μM dexamethasone profoundly agitated the rats causing them 
to damage the probe or connecting tubing and, in one instance, injuring themselves. The 
biological half-life of dexamethasone is 36-54 hrs (Marcus HJ, 2010), so it is likely that the 
continuous perfusion led to a cumulative dosing effect. 
4. HPLC analysis 
The microdialysis samples were analyzed by capillary HPLC coupled to a highly sensitive 
electrochemical detector.  The mobile phase was delivered with a NanoLC Ultra pump (Eksigent 
Technologies, Dublin, CA) at 2 µL/min without the use of a splitter.  The sample injection valve 
(VICI Valco Instruments, Houston, TX) had a 500-nL fused silica capillary sample loop. The 
fused silica capillary columns (5.5-6.5 cm long, 100 µm i.d., and 365 µm o.d.) were packed in-
house with Waters 2.6 µm XTerra C18 MS stationary phase (Waters, Milford MA) by the slurry 
method.  Mobile phases were prepared by mixing acetonitrile (4%) with aqueous buffer (96%) 
containing 100 mM sodium acetate, 0.15 mM disodium EDTA, and 18 mM sodium octyl sulfate 
adjusted to pH 4 with acetic acid.  The mobile phase was passed through a 0.20 µm Nylon filter 
prior to use (Fisher Scientific, Pittsburgh, PA).  A short length of 25 µm i.d. fused silica capillary 
acted as a connecter between the column and a radial-flow electrochemical detector with a BASi 
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radial style auxiliary electrode, a thin (13 µm) Teflon spacer and a lab-made glassy carbon 
working electrode block.  A BASi Epsilon potentiostat controlled the detection potential at +0.7 
V vs. Ag/AgCl (3 M NaCl). This system separated dopamine from other electroactive species in 
less than 3 minutes (Figure I.1). Detection limit is 1.0 nM (three times signal to noise) and 
quantification limit is 3.2 nM (ten times signal to noise). Calibration curves were established on 
the same day as analysis with freshly prepared standard solutions (Figure I.1, inset). 
5. Dopamine extraction curves 
Dopamine extraction curves were obtained by perfusing the probes with 0, 100, 250, or 1000 nM 
dopamine and 50 μM ascorbate as a preservative.  This range of dopamine concentrations is 
wider than typically used: most studies of dopamine extraction are confined to the 0-200 nM 
range (Smith & Justice, 1994; Bungay et al., 2007), although serotonin and norepinephrine have 
been studied over the 0-400 nM range (Cosford et al., 1996).  The selection of a wider 
concentration range here was based on preliminary results that indicated the non-linear character 
of the dopamine extraction curves obtained in the presence of dexamethasone (see Results and 
Discussion).  The wider concentration range allowed a more thorough investigation of the 
nonlinear character of the extraction curves.  After changing the composition of the perfusion 
fluid, probes were perfused for 1 hr, after which a 1 hr sample was collected into a glass 
microvial containing 4 μL of 0.5 M acetic acid (the acetic acid acidified the samples and 
protected the dopamine from air-oxidation during the 1-hr collection).  Samples were stored on 
dry ice and analyzed in triplicate by HPLC as soon as possible after sample collection, usually on 
the same day as collection. The results were used to construct dopamine extraction curves, as 
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explained in the following paper.  The extraction curves were analyzed by linear or quadratic 
regression with OriginPro 7.5 (OriginLabs, Northampton, MA). 
 
Figure I.1 A) A typical chromatogram of a brain dialysate sample obtained by capillary HPLC coupled to a radial-
flow electrochemical detector with a thin (13 µm) Teflon spacer. This sample was obtained 1 day after probe 
implantation: the probe was perfused with dexamethasone and dopamine (1000 nM). B) A typical calibration curve 
for dopamine. 
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6. Tissue fixation and processing 
After 5 days of continuous microdialysis, rats underwent transcardial perfusion with 160 ml 
PBS, 160 ml of 4% paraformaldehyde in PBS, and 50 ml of a 0.1% suspension of fluorescent 
beads (0.1 μm diameter) in PBS.  The brain was submerged in 4% paraformaldehyde for 2 hours 
and then in 30% sucrose overnight.  The brain was frozen by dipping in liquid nitrogen-cooled 2-
methylbutane and stored at -80°C until sliced horizontally in a cryostat into 30-μm thick 
sections.  The sections were mounted onto glass slides and stored at -20°C until further use. 
7. Immunofluorescence protocol and fluorescence microscopy 
Standard protocols were used to label the thin tissue sections with antibodies for glial fibrillary 
acidic protein, GFAP, a well-known marker for astocytes, one type of glial cell involved in 
gliosis.  Sections were also treated with DAPI to aide in the visualization of neuronal and glial 
nuclei.  Fluorescence microscopy (Olympus BX61, Olympus; Melville, NY) was performed with 
a 10X or 20X objective and appropriate filter sets (Chroma Technology; Rockingham, VT) for 
visualization of the beads, GFAP antibody, and DAPI-labeled nuclei. The images were analyzed 
with the Metamorph/Fluor 7.1 software package (Universal Imaging Corporation; Molecular 
Devices) and quantified with Metamorph and OriginPro. 
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C. RESULTS AND DISCUSSION 
1. Microdialysis probes induce gliosis 
GFAP immunofluorescence reveals profound gliosis at the tracks of microdialysis probes after 5-
day perfusions in the rat brain (Figure I.2).  The GFAP image from the non-implanted brain 
hemisphere (Figure I.2A) resembles that from non-implanted rats (Supplementary Figure I.9).  
Glia surrounding the probe tracks exhibit enlarged cell bodies and thickened and elongated 
processes (Figure I.2B).  The images in Figure I.1 extend our previous report that gliosis is 
evident after 24-hr perfusions (Hascup et al., 2009).  These longer perfusions are relevant to the 
neurointensive care applications of microdialysis (Fabricius et al., 2008; Feuerstein et al., 2010). 
2. Dexamethasone inhibits gliosis  
After 5-day perfusions without dexamethasone microdialysis probes are fully engulfed by a glial 
barrier (Figure I.3).  The glial barriers were continuous around the entire circumference of the 
tracks, which maintained their symmetrical shape even when the probes were withdrawn to 
section the tissue (Figure I.3B).  The rigidity of the glial barrier is attributable to the 
proteoglycan secretions of activated glia (Laabs et al., 2007).  Dexamethasone inhibited the 
gliosis resulting in a residual, discontinuous, non-rigid glial barrier (Figure I.3C).  
Dexamethasone-perfused tracks showed more GFAP labeling than non-implanted tissues (Figure 
I.3A) but less than tracks perfused without dexamethasone (Figure I.3B).  After perfusion with 
dexamethasone, the tracks did not maintain their open circular shape during tissue processing, so 
they appear distorted and non-symmetric in the images. 
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Figure I.2 The effect of a microdialysis probe on striatal glial cells labeled with GFAP antibody.  A) Striatal tissue 
from a non-implanted brain hemisphere (contralateral to the probe).  B) Striatal tissue next to a microdialysis probe 
track: the edge of the track is on the left side of the image.  The right-hand column shows enlargements of the white 
boxes in panel B.  
 
 Figure I.3 Retrodialysis of dexamethasone inhibits gliosis. A) GFAP image of striatal tissue from a non-implanted 
hemisphere contralateral to a microdialysis probe.  B) GFAP image of a glial barrier formed after 5 days of 
microdialysis without dexamethasone.  C) GFAP image of a probe track after 5 days of retrodialysis of 
dexamethasone.   
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3. Dexamethasone prevents ischemia 
5-day perfusions without dexamethasone caused profound ischemia, as evidenced by a near-total 
absence of bead-labeled blood vessels near the probe tracks (Figure I.4, right panel).  However, 
after 5-day perfusions with dexamethasone bead-laden vessels near the tracks appear essentially 
normal (Figure I.4, left panel).  Thus, dexamethasone, in addition to inhibiting gliosis, also 
prevented ischemia at the probe tracks. 
4. Objective analysis of GFAP images 
Using Metamorph, we converted 9 images (3 non-implanted, 3 without dexamethasone, and 3 
with dexamethasone) to color-coded surface intensity plots (see Supplementary Figure I.10) and 
then to binned intensity histograms (Figure I.5).  In control images (blue, Figure I.5), the 
majority of pixels are in the lowest intensity bin (0-43) because GFAP labeling is sparse in these 
tissues.  Perfusion without dexamethasone decreases the number pixels in the lowest intensity 
bin (0-43) and increases the number of pixels in all higher intensity bins (44-255), reflecting the 
increased GFAP labeling in these tissues (red, Figure I.5).  Dexamethasone returned the number 
of pixels in the higher intensity bins (>129) to control levels and increased the number of pixels 
in the low intensity bins (<128), providing a quantitative measure of the inhibition of gliosis by 
perfusion with dexamethasone. 
We also used Metamorph to construct line-scan intensity profiles of the GFAP images 
(Figure I.6).  The lines were arranged like “spokes” surrounding a “hub” (Figure I.6B) centered 
on the probe track (in non-implanted control tissue, the hub was centered within the striatum).  
The line-scans from non-implanted tissues (blue, Figure I.6C) exhibit only minor variations in 
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intensity with distance from the hub.  The line-scans from probe tracks (red and green, Figure 
I.6C) show a region of low intensity near the center of the track where there is no GFAP 
labeling: the size of this region is affected by the asymmetry of the tracks (see Figure I.3).  The 
line-scans from tissues perfused with (green) and without (red) dexamethasone show the profiles 
of the respective glial barriers.  Dexamethasone substantially diminished the height and width of 
the glial barrier profile. 
5. Objective analysis of blood vessel images 
We also used Metamorph software to compare the number of fluorescent pixels in the blood 
vessel images from implanted and non-implanted tissues. The images were centered on the 
striatum (non-implanted controls) or the probe tracks (implanted tissues).  The results, 
normalized to the average pixel count from six non-implanted controls, show that in tissues from 
rats perfused for 5 days without dexamethasone, the number of fluorescent pixels was reduced to 
4.4% (red, Figure I.7), reflecting profound probe-induced ischemia.  In tissues from rats perfused 
for 5 days with dexamethasone, the number of fluorescent pixels was reduced to 42.8% (green, 
Figure I.7), mainly because the images contained the probe track where blood vessels are 
completely absent.  Thus, Figure I.7 confirms quantitatively that dexamethasone inhibited probe-
induced ischemia. 
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Figure I.4 A montage of the tissue response after 5 days of microdialysis with (left) and without (right) of 
dexamethasone.  Note the complete absence of nanobeads in the right hand column, indicating profound ischemia in 
this tissue.  The position of the microdialysis probe track is at the far left in both panels. 
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Figure I.5 Comparison of the pixel intensity distribution in images of non-implanted (control) tissue (blue) and 
tissue dialyzed without (red) and with (green) dexamethasone.  The data are reported as the mean and standard 
deviation of the number of pixels in each intensity bin from three images. 
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Figure I.6 Line scan analysis of GFAP images. A) Non-Implanted control tissue. B) The same image overlaid with 
the spoke pattern of lines used to construct the line-scans in C. C) Line scan intensity profiles obtained from non-
implanted control tissue (blue) and from tissue dialyzed without (red) and with (green) dexamethasone. Data are 
reported as the mean (solid line) and the standard deviation (dotted line) of 36 lines per image. 
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Figure I.7 The number of fluorescent pixels in blood vessel images from non-implanted control tissues (blue) and 
implanted tissues perfused with (green) and without (red) dexamethasone: the data are normalized with respect to 
the average pixel count from the non-implanted controls. Tissue with and without dexamethasone were significantly 
different from one another and from non-Implanted tissue (ANOVA and Tukey posthoc test: F(2,12) = 57.1; p < 
0.00001). 
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6. The effect of dexamethasone on dopamine no-net-flux 
Because the impact of dexamethasone on gliosis and ischemia is readily apparent, we became 
interested in knowing how the drug might affect microdialysis results.  To investigate this, we 
measured no-net-flux curves for dopamine, an important neurotransmitter and the subject of 
prior microdialysis studies (Justice, 1993; Yang et al., 1998; Bungay et al., 2003; Borland & 
Michael, 2004; Borland et al., 2005; Perry et al., 2009). 
Microdialysis extraction curves (see Supplementary Information) are usually linear and 
aptly described by the following equation (Michael et al., 2005): 
𝐶𝑖𝑛 − 𝐶𝑜𝑢𝑡 = 𝐸 ∙ 𝐶𝑖𝑛 − 𝑅 ∙ 𝐶𝑒𝑥𝑡    (Equation 1) 
where Cin and Cout are the concentrations at the inlet and outlet of the probe, Cext is the 
concentration outside the probe, R is the recovery factor, and E is the extraction factor.  Since R 
and Cext are not separable during in vivo experiments, it is practical to replace R∙C ext with Cout 
measured when Cin is zero, which is known as the conventional microdialysis result, Cout,c: 
𝐶𝑖𝑛 − 𝐶𝑜𝑢𝑡 =  𝐸 ∙ 𝐶𝑖𝑛 − 𝐶𝑜𝑢𝑡,𝑐    (Equation 2) 
According to Equation 2, Cout,c is the inverse of the y-intercept of the extraction curve and E is its 
slope. The x-intercept of the extraction curve corresponds to the condition that Cin and Cout are 
equal to each other: their common value is called the no-net-flux concentration, Cnnf (Bungay et 
al., 2003; Michael et al., 2005; Chefer et al., 2006; Bungay et al., 2007). 
Using probes perfused without dexamethasone, the dopamine extraction curves measured 
on day 1 and day 4 (red, Figure I.8) exhibited typical features: the curves were linear with Cout,c 
and Cnnf values near 10 nM (Kulagina et al., 2001) (see also Table 1).  Dexamethasone had no 
significant effect on the values of Cout,c and Cnnf (Table 1).  To us, this came as a surprise, as we 
had anticipated that inhibiting gliosis and ischemia might increase Cout,c and Cnnf towards the 
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higher in vivo dopamine concentrations we have measured with microelectrodes (Peters & 
Michael, 1998; Borland & Michael, 2004; Wang et al., 2010).  This suggests that even though 
dexamethasone inhibited gliosis and ischemia, it did not protect dopamine terminals from the 
penetration injury. 
Interestingly, however, the extraction curves measured in the presence of dexamethasone 
appear to be non-linear (green, Figure I.8 and Table 1).  The most likely explanation for this 
involves the Michaelis-Menten kinetics of the dopamine transporter, the protein responsible for 
the uptake of dopamine by brain tissue.  The transporter aids the extraction of dopamine from the 
microdialysis probe by enabling nearby brain tissue to take up dopamine after it diffuses out of 
the probe, as originally explained by Smith and Justice (Smith & Justice, 1994).  Since the 
transporter has a KM value near 200 nM, it is surprising that the extraction curves are linear, as 
we observed in the absence of dexamethasone, even when the Cin values substantially exceed 
KM.  This indicates that the dopamine is diluted by the time it diffuses to the transporter, such 
that the transporter does not become saturated with dopamine.  The non-linear extraction curve 
observed with dexamethasone, then, suggests that dopamine more readily diffuses to the 
transporter, consistent with a reduction of the glial barrier next to the probe, making it easier to 
saturate the transporter. 
Previous microdialysis studies have concluded that steroid use inhibits dopamine uptake, 
(Becker & Cha, 1989; Castner et al., 1993; Pacak et al., 2002; Sadri-Vakili et al., 2003) 
prompting speculation that steroids possess a cocaine-like activity that exacerbates their abuse by 
some users.  However, the authors of those prior studies were likely unaware that steroids might 
have indirect effects on dopamine uptake due to alterations in the tissue reaction to the 
  24 
microdialysis probe.  This illustrates that hidden subtleties can impact the interpretation of in 
vivo analytical measurements. 
D. CONCLUSION 
The results of this study support the conclusion that dexamethasone is highly effective at 
preventing the gliosis and ischemia triggered by the penetration injury that accompanies the 
implantation of microdialysis probes into brain tissue, while offering relatively little 
neuroprotection per se to the dopamine terminals.  Nevertheless, we speculate that inhibiting 
gliosis and ischemia is likely a necessary component of an overall neuroprotective strategy, as 
activated glia destroy neurons and their processes and prevent their regrowth (Goritz et al., 2002; 
Stroncek & Reichert, 2008).  So, we expect that dexamethasone will contribute to mitigating 
probe-induced injury, especially if combined with complementary neuroprotective measures (e.g. 
the use of glutamate antagonists, antioxidants, or radical scavengers, etc.).   In closing, we note 
that there may be restrictions on the uses of dexamethasone, which has failed human trials as a 
therapeutic agent for traumatic brain injury: human trials were terminated early because 
dexamethasone increased mortality (Alderson & Roberts, 1997). 
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Figure I.8 Dopamine concentration difference plots obtained in the rat striatum on day 1 (A) and day 4 (B) of 
microdialysis with (green) and without (red) dexamethasone.  The data points represent the mean ± the standard 
error.  The solid lines show the linear regression of the data obtained without dexamethasone (red) and the quadratic 
regression of the data obtained with dexamethasone (green).  Insets expand the region near the origin to visualize 
Cout,c and Cnnf. 
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Table 1 Dopamine no-net-flux measurement. 
Parameter 
Day 1 Day 4 
Without DXM 
N = 3 
With DXM 
N = 6 
Without DXM 
N = 3 
With DXM 
N = 3 
Conventional 
Microdialysis 
Concentration 
(Cout, c), nMa 
9.19 ± 3.49 11.94 ± 5.36 16.49 ± 8.85 19.11 ± 3.41 
No-net-flux 
Concentration 
(Cnnf), nMb 
9.34 ± 7.17 16.26 ± 1.54 19.07 ± 4.19 19.37 ± 1.61 
Extraction 
Fraction (E)c 0.901 ± 0.010  0.858 ± 0.008  
Regression 
Equationc 
Y = Cin – Cout 
X = Cin 
Y = 0.901X – 9.02 Y = -2.1×10
-4X2 
+ 0.76X – 15.78 
Y = 0.858X − 
10.02 
Y = -4.6×10-4X2 
+ 1.20X – 25.07 
Coefficient of 
Determination 
(r2)c 
0.9996 0.9997 0.9997 0.9987 
a: Determined by direct measurement. 
b: Determined by regression of data from individual animal. 
c: Determined by regression of averages across animals. 
  
  27 
E. SUPPLEMENTARY INFORMATION 
1. Microscopy of non-implanted control tissues 
Images of 30-μm thick horizontally-cut sections of the non-implanted rat striatum (control tissue) 
exhibit the normal structure and morphology of this brain region (Supplementary Figure I.9).  
DAPI-labeled nuclei (blue, Supplementary Figure I.9A) are distributed uniformly with no 
obvious voids or clusters.  Bead-laden blood vessels (green, Supplementary Figure I.9B) are 
spaced on-average 60 μm apart, with some vessels appearing in profile and some appearing in 
cross-section.  Most vessels are capillaries but larger vessels are observed occasionally.  The 
beads are confined to the vessels and do not reach the interstitial spaces, because brain 
endothelial cells form tight junctions.  GFAP-labeled glial cells (red, Supplementary Figure I.9C) 
appear star-like, hence the name astrocyte, are sparsely distributed, and exhibit numerous fine 
processes.  An overlay image of the blood vessels and astrocytes shows points of contact 
(yellow, Supplementary Figure I.9D), consistent with the role glia play in transporting 
substances from vessels to brain cells.  The differential interference contrast (DIC) image 
(Supplementary Figure I.9F) shows that the tissue is uniform and free of defects. 
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Figure I.9 Microscopy of non-implanted striatal tissue. A) nuclei labeled with DAPI, B) blood vessels labeled with 
fluorescent beads,  C) glial cells (astrocytes) labeled with GFAP antibody, D) overlay of B and C (note yellow pixels 
indicating contact between glial cells and blood vessels), E) overlay of A, B, and C, F) DIC image. 
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2. Color-coded intensity plots 
For quantitative image analysis, we used Metamorph software to convert the fluorescent GFAP 
images to color-coded surface intensity plots (Supplementary Figure I.10): the intensity range 
was 0-255 (low-high).  In non-implanted tissues (Supplementary Figure I.10A) occasional spots 
of medium intensity (yellow) correspond to normal glial cells.  In tissues perfused without 
dexamethasone (Supplementary Figure I.10B), the increased number and intensity of the GFAP 
spots reflect both the proliferation and enlargement of the glial cells.  These features are absent 
in the tissues perfused with dexamethasone (Supplementary Figure I.10C). 
3. Dopamine extraction curves 
Table 1 reports the numerical values of Cout,c and Cnnf for dopamine measured in the rat striatum.  
Cout,c was determined by HPCL analysis of dialysate samples collected when Cin was zero.  Cnnf 
was determined by regression analysis of the extraction curves.  Linear regression of the results 
obtained without dexamethasone produced r2 values greater than 0.999.  However, in the case of 
the results obtained with dexamethasone, high regression coefficients required quadratic 
regression.  
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Figure I.10 A color-plot representation of the GFAP images of non-implanted striatal tissue (A) and striatal tissue 
dialyzed without (B) and with (C) dexamethasone.  Pixel intensities are color coded from 0 to 255 as indicated on 
the color scales next to the images. Scale bars = 100 µm. 
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CHAPTER II.  THE DOPAMINE PATCHWORK OF THE RAT NUCLEUS 
ACCUMBENS CORE 
Adapted with revision from Zhan Shu, I. Mitch Taylor and Adrian C. Michael (2013) European 
Journal of Neuroscience, 38, 3221-3229. 
A. INTRODUCTION 
Dopamine (DA) is critically important in numerous aspects of normal CNS function (O'Donnell, 
2003; Schultz, 2007) and the etiology of several CNS disorders, including Parkinson’s disease 
(Schultz, 1982; Lotharius & Brundin, 2002), schizophrenia (Abi-Dargham et al., 2000), 
substance abuse (Phillips et al., 2003), and attention deficit hyperactivity disorder (Sagvolden et 
al., 2005). DA’s diversity of function and dysfunction imparts deep significance to understanding 
the mechanisms that control extracellular DA concentrations and their spatiotemporal dynamics.  
Such mechanisms have been extensively studied in the subregions of the striatum (i.e. dorsal 
striatum and nucleus accumbens) that play central roles in motor control (Kish et al., 1988; 
Graybiel et al., 1994; Doya, 2000; Durieux et al., 2012) and the mediation of reward-related 
behaviors (Schultz, 1998; Ikemoto & Panksepp, 1999; Wise, 2004; Ariansen et al., 2012). 
The kinetics of evoked DA release and DA clearance in the striatum are heterogeneous 
(May & Wightman, 1989; Garris et al., 1994b; Zachek et al., 2010). Consequently, it has become 
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common practice during voltammetric recording of extracellular DA to seek out “hot spots”, i.e. 
recording sites that produce maximally robust DA responses.  The concept of hot spots, however, 
is inconsistent with the ultrastructure of the striatum, which contains a regular array of DA 
terminals arranged in a lattice-like formation (Moss & Bolam, 2008).  Thus, a truly 
comprehensive understanding of dopaminergic mechanisms requires knowledge also of the 
properties and functions of sites that do not qualify as hot spots. 
Voltammetric DA recordings in the dorsal portion of the rat striatum have revealed the 
presence of a patchwork of domains exhibiting significant differences in the kinetics and 
plasticity of evoked DA release, the kinetics of DA clearance, and the actions of several 
dopaminergic drugs (Moquin & Michael, 2009; Wang et al., 2010; Moquin & Michael, 2011, 
Taylor et al., 2012 & 2013).  These differences derive, in part, from local variations in DA’s 
basal concentration, which establishes an autoinhibitory tone in the slow, but not the fast, 
domains.  The objective of the present study was to address the hypothesis that a domain 
patchwork might exist also in the core of the nucleus accumbens (NAcc).  Our findings confirm 
the existence of a domain patchwork in the NAcc but also show that the NAcc domains are 
substantially different from those in the dorsal striatum. 
B. MATERIALS AND METHODS 
1. Solutions, drugs, and reagents 
All reagents were used as-received from their suppliers and all aqueous solutions were prepared 
in ultrapure water (NANOPure, Barnstead, Dubuque, IA, USA).  Dopamine hydrochloride 
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(Sigma-Aldrich, St. Louis, MO, USA) standard solutions were prepared fresh just before use in 
N2-purged artificial cerebrospinal fluid (aCSF, 144 mM Na+, 1.2 mM Ca2+, 2.7 mM K+, 149.1 
mM Cl-, 1.0 mM Mg2+, 2.0 mM phosphate, pH 7.4).  Raclopride tartrate (Sigma-Aldrich) was 
dissolved in phosphate buffered saline (PBS, 155 mM NaCl, 100 mM sodium phosphate, pH 
7.4).  Paraformaldehyde (PFA, 4% in PBS) was prepared from resin (Sigma-Aldrich) and stored 
at 4 °C. 
2. Carbon fiber electrodes 
Single carbon fibers (7-μm diameter T650, Cytec Carbon Fibers, LLC, Piedmont, SC, USA) 
were placed inside fire polished borosilicate glass capillaries (0.58 mm I.D., 1.0 mm O.D.; Sutter 
Instruments, Co., Novato, CA, USA).  Each capillary was pulled to a fine tip (Narishige puller, 
Tokyo, Japan) and sealed with low-viscosity epoxy (Spurr Embedding Kit, Polysciences, Inc., 
Warrington, PA, USA).  The exposed fiber was trimmed to 200 μm with a surgical blade and an 
electrical connection between the fiber and a Ag-coated copper wire (Squires Electronics, Inc., 
Cornelius, OR, USA) was formed with a droplet of mercury. The electrode tip was immersed in 
purified reagent-grade isopropyl alcohol (Sigma-Aldrich) for at least 20 min (Bath et al., 2000). 
3. Fast-scan cyclic voltammetry (FSCV) 
FSCV was performed with a custom-built potentiostat (electronics shop, Department of 
Chemistry, University of Pittsburgh) and a current amplifier (Keithley 428, Keithley Instruments, 
Inc., Cleveland, OH, USA) under software control (CVTarHeels 4.3, courtesy of Prof. Michael 
Heien, Department of Chemistry, University of Arizona (Heien et al., 2003)) running on a PC 
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equipped with analog interface boards (PCI-6052E and PCI-6711, National Instruments, Austin, 
TX, USA).  The potential between scans was 0 V vs. Ag/AgCl.  The triangular potential 
waveform (three linear sweeps to 1.0 V, then to -0.5 V, and back to 0 V at 400 V/s) was repeated 
at 10 Hz. 
4. Electrode calibration 
Electrodes were pre- and post-calibrated in DA standard solutions using a custom-built flow cell 
(University of Pittsburgh, Department of Chemistry Mechanics Shop) with gravity-fed aCSF. In 
vivo DA concentrations were determined by post-calibration. 
5. Subjects 
Protocols were in accordance with NIH guidelines (publication 86-23). The Institutional Animal 
Care and Use Committee of the University of Pittsburgh approved all procedures involving 
animals (male Male Sprague-Dawley rats, n = 38, 250-275 g, Hilltop Laboratories, Scottsdale, 
PA, USA). 
6. Surgery 
Rats were anesthetized with isoflurane (5% by vol. initially and 2.5% for maintenance) delivered 
via a ventilator (Harvard Apparatus, Holliston, MA, USA) and wrapped in a 37 °C 
homoeothermic blanket (Harvard Apparatus).  A carbon fiber electrode was placed into the 
dorsal striatum (AP +1.2 mm, ML +1.4 mm, DV 5.0 mm below dura, (Paxinos & Watson, 1998) 
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and a Ag/AgCl reference electrode (Bioanalytical Systems Inc., West Lafayette, IN, USA) was 
placed in contact with the contralateral cortical surface via a salt bridge.  A bipolar, stainless-
steel stimulating electrode (MS303/B, Plastics One, Inc., Roanoke, VA, USA) was placed just 
above the ipsilateral medial forebrain bundle (MFB) (AP -4.3 mm, ML +1.2 mm, DV 7.5 below 
dura) and then slowly lowed until evoked DA release was detected in the striatum (Ewing et al., 
1983; Kuhr et al., 1984; Michael et al., 1987).  Thereafter, without moving the stimulating 
electrode the carbon fiber was slowly lowered into the NAcc (DV 6.6-7.6 mm below dura).  
Consistent with prior reports (Kuhr et al., 1986; Stamford et al., 1988; Garris et al., 1994b), 
electrical stimulation of the MFB evoked DA release in the dorsal striatum and NAcc. 
In a separate group of rats, once the carbon fiber was positioned in the NAcc, stimulation 
(60 Hz, 250 μA, 3 s) was repeated at 5-min intervals.  Between each stimulus the stimulating 
electrode was lowered slowly through the MFB in 100 μm vertical steps (results in 
Supplementary Figure II.13). 
7. Electrical Stimulation 
The electrical stimulus was a constant-current, biphasic square wave (duration 0.2-3 s, frequency 
60 Hz, pulse intensity 150-550 μA, pulse width 2 ms) supplied by a pair of optical stimulus 
isolators (NL800A, Digitimer, Ltd., Letchworth Garden City, UK).  When multiple consecutive 
trains were used, the four trains were 1-s long and separated by a 2-s interval. 
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8. Drug administration 
Each rat received a series of pre-raclopride stimuli, a single dose of raclopride (2 mg/kg i.p.), and 
a final post-raclopride stimulus 30 min after drug administration. 
9. Histology 
A small lesion (12 V AC, 3-5 s) was used to identify the recording sites because carbon fiber 
tracks are otherwise not visible by light microscopy (Peters et al., 2004).  Because the lesion 
procedure destroys the electrode, it was performed after electrode post-calibration: electrodes 
were retracted from the tissue, post-calibrated, and returned to their final stereotaxic coordinates 
for the lesion procedure.  Every possible effort was made not to disturb the way the electrode 
was mounted on the carrier arm during post-calibration.  After the lesion, rats were perfused via 
the heart with 160 mL PBS followed by 160 mL PFA.  Brain tissue was removed from the skull, 
stored in cold PFA, cut into 30 μm coronal sections (Vibratome, St. Louis, MO, USA), stained 
with cresyl violet, cover-slipped, and examined with a light microscope (Leica Microsystems).  
All results reported herein are from recording sites in the NAcc (Supplementary Figure II.8). 
10. Data analysis 
The initial rate of evoked dopamine overflow was determined from the slope of the evoked 
responses during the first 300 ms of each electrical stimulus.  The linear dopamine clearance rate 
was measured from the slope of the descending phase of the responses after the stimulus: linear 
segments were defined by at least three data points with an r2 > 0.96. Overshoot duration was 
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defined by the time needed after the end of the stimulus for the evoked response to reach its 
maximum amplitude. The overshoot concentration was the amount by which the dopamine 
concentration continued to increase after the end of the stimulus. Statistical analyses were by t-
test and two-way analysis of variance (ANOVA) with a repeated measures design (IBM SPSS 
Statistics 20). 
C. RESULTS 
1. DA shows two distinct kinetic profiles in NAcc 
Electrically evoked DA release in the NAcc exhibits two distinct kinetic profiles, depending on 
the recording location, within individual animals (Figure II.1).  During a brief stimulus (200 ms, 
60 Hz, 250 μA) the fast kinetic profile (Figure II.1, solid line) exhibits evoked DA release 
without delay when the stimulus begins and short-term facilitation of release as the stimulus 
proceeds: short-term facilitation is evident in the greater increase in DA caused by the second 
100 ms of the stimulus compared to the first 100 ms.  When the stimulus ends, the DA signal 
continues to increase (overshoot) for an additional 200 ms before starting to return towards the 
baseline.  In contrast, a slow recording location in the same animal exhibits no response (Figure 
II.1, dashed line).  However, if the stimulus is extended to 1 s, the slow profile (Figure II.1, dash-
dot line) exhibits robust DA release after a ~200-ms initial delay.  The slow profile also exhibits 
short-term facilitation and overshoot.  The presence or absence of the initial ~200-ms delay in 
evoked release provides an objective basis for classifying NAcc responses as fast or slow, 
respectively. 
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Figure II.1 Two types of evoked dopamine responses in NAcc.  A brief stimulus (200 ms, 60 Hz, 250 μA) evokes 
both a fast (solid line) and slow (dashed line) profile at two recording sites within the NAcc of a single rat.  A longer 
stimulus (1 s, 60 Hz, 250 μA) evokes a slow profile after a 200 ms initial delay (dash dot delay).   In this and 
subsequent figures, solid circles and triangles mark the start and end of the stimulus, respectively. 
 
The fast and slow NAcc profiles are consistent across multiple animals (Figure II.2: 
stimulus = 1 s, 60 Hz, 250 μA: solid lines are the average of multiple fast (n = 8) and slow (n = 
8) profiles recorded in separate rats: the dotted lines are confidence intervals based on the SEMs: 
the same presentation format is used in subsequent figures).  The responses are significantly 
different (see ANOVA results in the figure legend).  These two profiles completely define 
evoked DA responses in the NAcc, i.e. no other profiles were detected.  The maximum 
amplitude (Figure II.2b), initial rate of overflow (Figure II.2c), and rate of DA clearance after the 
stimulus (Figure II.2d) are significantly profile-dependent.  However, the two profiles exhibit 
  39 
similar overshoot duration (Figure II.2e).  Whether a fast or slow profile is observed at any given 
recording location is not determined by the location of the stimulating electrode (Supplementary 
Figure II.13). 
 
Figure II.2 Comparison of fast and slow responses during a 1-s stimulus.  In this and subsequent figures, the solid 
lines and symbols report the average of profiles recorded in multiple animals and the dotted lines report the 
confidence interval based on the SEM of each data point.  (a) The profiles are the average of 8 fast (diamond) and 8 
slow (square) responses.  The difference between fast and slow profiles is significant (all data from 0.1 to 2.9 s, two-
way ANOVA with a repeated measures design: domains F(1,14) = 12.051; n = 16; p < 0.005). The maximum 
amplitude (2b, independent-samples t-tests, *p < 0.005), initial rate of overflow (2c, independent-samples t-tests, 
**p < 0.001), and rate of DA clearance after the stimulus (2d, independent-samples t-tests, *p < 0.005) are 
significantly profile-dependent. The overshoot duration is not significantly (2e, independent-samples t-tests, p > 0.5) 
different between fast and slow profiles. 
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2. Effects of current intensity 
Distinct fast and slow NAcc profiles are consistent over a broad range of stimulus current 
intensities (Figure II.3, stimulus = 3 s, 60 Hz, 150-550 μA: SEM ranges omitted for clarity).  At 
intensities ≥300 μA and ≥450 μA the fast and slow profiles, respectively, exhibit a constant 
initial rate of DA clearance (see also Supplementary Figure II.9a): this indicates saturation of DA 
clearance and justifies the use of the observed clearance rates as the apparent Vmax of DA uptake 
in each domain.  The apparent Vmax of the fast profile, 3.90 ± 0.57 μM/s (n = 4), is significantly 
(p < 0.05) higher than that of the slow profile, 2.24 ± 0.22 μM/s (n = 6). 
 
Figure II.3 Effects of current intensity on evoked DA overflow.  Average fast (n=4) and slow (n=6) profiles as a 
function of stimulus intensity (3 s, 60 Hz, 150-550 μA).  Error bars and symbols for individual data points omitted 
for clarity. The maximum DA amplitude (independent-samples t-test, p < 0.05) and initial rate (0-0.3 s, independent-
samples t-test, p < 0.05) are significantly profile-dependent across all 150-550 μA intensities.  See Supplementary 
Figure II.S9b for information on the rate of linear clearance after the stimulus. 
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3. Short-term facilitation of NAcc fast DA release 
The NAcc fast profile exhibits short-term facilitation of DA release, whereas the dorsal-striatum 
fast profile exhibits short-term depression (Moquin & Michael, 2009).  Since this is a unique 
aspect of the NAcc response, we examine it in more detail here (Figure II.4).  During brief 
stimuli over a range of current intensities (200 ms, 60 Hz, 150-550 μA), the slow profiles exhibit 
either no or minimal evoked DA release but the fast profiles exhibit a steady increase in 
maximum response amplitude.  However, after the first 100 ms of the stimulus, the amplitude of 
DA release in the fast profile is independent of the stimulus intensity (Supplementary Figure 
II.10).  The amplitude increases steadily with stimulus intensity during the second 100 ms of the 
stimulus (short-term facilitation) and during the 100 ms after the stimulus ends (overshoot).  
 Figure II.4 Short-term facilitation in NAcc fast domains.  Average profiles recorded in fast (n = 4) and slow (n = 6) 
domains during brief stimuli as a function of stimulus intensity (200 ms, 60 Hz, 150-550 μA). Error bars omitted for 
clarity.  The difference between fast and slow response maximum DA amplitude at all current intensities is 
significant (one sample t-test, 150-300 μA, p < 0.05; independent-samples t-test, 350-550 μA, p < 0.05).  See 
Supplementary Figure II.10 for information on the amplitude of release 100, 200, and 300 ms after the stimulus 
begins. 
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4. NAcc responses to multiple consecutive stimuli 
The NAcc yields distinct fast and slow profiles during consecutive stimuli (stimuli = 1-s pulse 
trains with 2-s intervals, 60 Hz, 250 μA, Figure II.5a).  The amplitudes of the fast and slow 
responses are significantly different (Fig 5b: two-way ANOVA with repeated measures F(1,14) = 
17.058, n = 16, **p < 0.001) but there are no significant train-to-train differences in amplitude in 
either domain.  Each consecutive train returned the DA concentration to the same absolute level 
(Figure II.5b).  When the response amplitudes were measured with respect to the signal at the 
beginning of each train, there was a slight but not significant decrease in the amplitudes 
normalized with respect to the first train (Figure II.5c).  Both the fast and slow profiles exhibit a 
~200 ms overshoot at the end of each consecutive train. 
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Figure II.5 Evoked dopamine overflow during multiple consecutive stimuli. (a) Average (± SEM) of individual 
responses: fast (solid line; n = 8 rats) and slow (dashed line; n = 8 rats) during four 1-s stimulus trains separated by 
2-s intervals (60 Hz, 250 μA). (b) The difference between fast and slow response in maximum DA amplitude in 
multiple stimulus trains is significant (two-way ANOVA with a repeated measures design; F(1,14) = 17.058; n = 16; 
**p < 0.001). (c) When the response amplitudes were measured with respect to the signal at the beginning of each 
train, there was a slight but not significant decrease in the amplitudes normalized with respect to the amplitude 
during the first train (two-way ANOVA with a repeated measures design; stimulation sequence p > 0.05 and 
domains p > 0.05). 
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5. Effects of raclopride 
Both the fast (Figure II.6) and slow (Figure II.7) NAcc profiles are sensitive to the D2 receptor 
antagonist, raclopride (2 mg/kg i.p.).  In both domains, raclopride increased the overall amplitude 
of the responses but had no significant effect on the first 100 ms of the fast profile or the first 200 
ms of the slow profile and had no significant effect on the rate of DA clearance after the end of 
the stimulus. Raclopride only significantly increased the overshoot duration of slow profiles 
(Figure II.7e, paired-samples t-test, p < 0.0005). 
 
Figure II.6 Effects of raclopride on fast profiles. (a) Average (± SEM, n = 6) of individual responses during 0.2 s 
stimulus (60 Hz, 250 μA). (b) Raclopride significantly (paired samples t-test; p < 0.05) increased the maximum DA 
amplitude. (c) Raclopride had no significant effect on the first 100 ms of the fast profile (paired samples t-test; p < 
0.05, only at 0.2 s). (d) Raclopride did not significantly affect the linear clearance rate or (e) overshoot duration of 
the fast profile. 
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Figure II.7 Effects of raclopride on slow profiles. (a) Average (± SEM, n = 6) of individual responses during 1-s 
stimulus (60 Hz, 250 μA). (b) Raclopride significantly (paired samples test; p < 0.05) increased the maximum DA 
amplitude. (c) Raclopride had no significant effect on the first 200 ms of the slow profile (paired samples test; p < 
0.05, only at 0.3 s). (d) Raclopride did not significantly affect the linear clearance rate. (e) Raclopride significantly 
(paired samples test; p < 0.0005) increased overshoot duration of the slow profile. 
D. DISCUSSION 
The findings presented herein confirm that the NAcc exhibits two distinct DA kinetic profiles.  
The nature, fast or slow, of evoked DA responses depends solely on the location of the recording 
electrode, so it appears that the DA terminal field of the NAcc is organized as a patchwork of 
fast and slow spatial domains, in similar fashion to the patchwork we have identified in the 
dorsal striatum (Moquin & Michael, 2009; Wang et al., 2010; Moquin & Michael, 2011, Taylor 
et al., 2012 & 2013).  Nevertheless, the NAcc domains are substantially different from those in 
the dorsal striatum in terms of short-term plasticity and the role of autoinhibition. 
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1. Patchwork vs. long-range diffusional distortion of evoked DA responses 
Prior studies of evoked DA release have tended to focus on “hot spots” and so the literature 
contains no prior reports of a DA patchwork in the NAcc.  Low-amplitude, delayed responses 
might be diffusional distortions of the fast responses (discussed by Taylor et al. 2012 & 2013) 
but several observations support the alternative view that the slow profiles reflect a distinct 
kinetic phenomenon.  For example, in the NAcc the fast and slow profiles exhibit no clear 
difference in the duration of the post-stimulus response overshoot (Figure II.2e).  The overshoot 
of the slow profiles would be longer if the slow profiles were derived from diffusion of DA from 
of fast domains.  Instead, we observe no domain difference in the time for the maximal DA 
concentration to reach the recording electrode.  Also, we observe a narrow range of response 
amplitude in the slow domains: this also speaks against a diffusion process because, if diffusion 
were involved, intermediate response amplitudes would be observed based on the distance 
between the electrode and the fast domains serving as the diffusion source.  Instead, our results 
show no evidence of a concentration gradient between NAcc fast and slow domains.  Our 
findings are much more consistent with DA diffusing within rather between the respective 
domains, a similar conclusion we have reached in the dorsal striatum (Taylor et al., 2012). 
2. Patchwork vs. short-range diffusional distortion 
In past studies, optimizing the recording site did not necessarily eliminate all signs of distortion 
by diffusion or the electrode response.  The response overshoot has been attributed to short-range 
diffusional distortion caused by a Nafion film on the electrode or possibility a distortion 
associated with DA absorption kinetics on the electrode surface (Engstrom et al., 1988; 
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Wightman et al., 1988; Kawagoe et al., 1992; Venton et al., 2002).  Several approaches have 
been developed to correct these distortions to gain access to the intrinsic kinetics of DA release 
and clearance (Garris et al., 1994a; Garris & Wightman, 1995; Garris et al., 1997; Wu et al., 
2001b; Addy et al., 2010).  However, our findings suggest that overshoot may also be a 
consequence of DA kinetics.  For example, we observe overshoots when recording brief 
responses (stimulus = 200 ms, 60 Hz, 250 μA) in the NAcc (Figure II.2) but not in the dorsal 
striatum (Moquin & Michael, 2009; Taylor et al., 2012).  During the present study, we confirmed 
that the same electrodes and recording technique that produce overshoots in the NAcc did not do 
so in the dorsal striatum (Supplementary Figure II.11).  Thus, the overshoot appears to be a 
feature of the NAcc rather than an inherent feature of the FSCV recording technique. 
3. The origin of overshoot in the NAcc 
The blockade of DA uptake with nomifensine dramatically increases overshoot duration and 
amplitude in the dorsal striatum (Taylor et al., 2012).  This raises the possibility that overshoots 
in the NAcc might be due to DA uptake, which is inherently slower in the NAcc than the dorsal 
striatum (Cass et al., 1992; Cass et al., 1993; Cragg et al., 2000; Wu et al., 2001a).  Although the 
apparent Vmax values for DA clearance in the fast and slow domains of the NAcc were 
significantly different, they were not significantly different from the corresponding values 
reported by the same experiment conducted in the dorsal striatum (Taylor et al., 2013 and 
Supplementary Figure II.9b).  However, in the NAcc, the domains did not exhibit any substantial 
difference in the time course of DA clearance (Supplementary Figure II.12): this is a stark 
contrast with the dorsal striatum, where the time course of DA clearance is domain-dependent 
(Moquin & Michael, 2011; Taylor et al., 2012).  So, DA clearance in the NAcc appears to 
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operate under near pseudo-first order conditions, especially at stimulus intensities <500 μA.  
Thus, we attribute the consistent overshoots in the NAcc to a higher value of the apparent KM of 
DA clearance. 
Our findings agree with prior reports that DA clearance is slower overall in the NAcc 
than in the dorsal striatum (Garris & Wightman, 1994; Wu et al., 2001a; Wu et al., 2001b).  
However, there appears to be some controversy over exactly why the rates of DA clearance are 
different between these two brain regions.  Prior studies have reported a regional difference in 
the Vmax, rather than the KM, of DA clearance (Jones et al., 1995; Wu et al. 2001a).  So, we were 
surprised to find no significant differences between the regional apparent Vmax values obtained 
during this study (Supplementary Figure II.9b).  It may be important to note that the apparent 
Vmax values reported herein were obtained by increasing the stimulus intensity until a constant 
rate of linear DA clearance was achieved (Supplementary Figure II.9), thereby confirming full 
saturation of the transporter.  Our study is unique in this regard, as no other in vivo studies have 
compared the apparent Vmax values in this exacting manner.  It should also be emphasized that 
we are reporting apparent kinetic parameters, whereas the prior studies reported intrinsic 
parameters obtained by means of diffusional corrections.  However, it remains to be seen if the 
corrections have fully accounted for the complex nature of diffusion in the brain extracellular 
space (Nicholson, 1995; Nicholson & Sykova, 1998; Sykova & Nicholson, 2008).  In vitro 
studies involving radiochemical methods also found differences in Vmax rather than KM (Near et 
al., 1988; Marshall et al., 1990) but Andrews and coworkers (Perez et al., 2007) have pointed out 
a number of technical challenges with such kinetic determinations. 
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4. Short-term facilitation in the NAcc 
In the dorsal striatum, the evoked DA release in the fast and slow domains exhibits marked 
short-term depression and facilitation, respectively, especially during multiple consecutive 
stimuli (Moquin & Michael, 2009).  This did not occur in the NAcc, where neither domain 
exhibited obvious plasticity during multiple consecutive stimuli (Figure II.5).  Thus, the short-
term plasticity of evoked release in the NAcc is dramatically different from that in the dorsal 
striatum. 
Short-term facilitation in the NAcc responses is apparent, however, during the rising 
phases of both the fast and slow profiles.  The details of short-term facilitation of the fast profiles 
are most clearly evident in the responses to 200 ms stimuli (Figure II.4, 60 Hz, 150-550 μA).   
The response amplitude 100 ms after the stimulus begins is independent of stimulus intensity 
(Supplementary Figure II.10).  But, the response amplitude at 200 and 300 ms after the stimulus 
begins increases steadily with the stimulus intensity.  These details are highly consistent with the 
restricted diffusion model we previously proposed to explain DA profiles in the dorsal striatum 
(Taylor et al., 2012).  According to this model, the diffusion of DA molecules in the extracellular 
space is restricted by dead space microdomains or binding sites (Nicholson, 1995; Nicholson & 
Sykova, 1998; Sykova & Nicholson, 2008).  Conventional diffusion occurs once DA release 
exceeds the tissue’s capacity to retain DA.  This model explains the temporal features of the 
NAcc responses.  For example, the longer initial delay in slow domains is due to the slow rate of 
evoked release, which causes a lower overall response amplitude but also increases the time 
needed to exceed the tissue’s capacity to retain DA.  The consistent overshoot duration in the fast 
and slow domains is due to DA exhibiting similar diffusion dynamics once the stimulus exceeds 
the tissue’s retention capacity. 
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Our finding of differences in the short-term plasticity of evoked DA release in dorsal 
striatum and NAcc is consistent with the prior reports of Cragg (2003) and of Yavich and 
coworkers (Chadchankar & Yavich, 2011).  Cragg (2003) reported short-term depression in 
tissue slices from the dorsal part of the primate striatum (putamen) and short-term facilitation in 
the nucleus accumbens.  Using a different stimulus protocol, Yavich and coworkers reported 
short-term facilitation in the dorsal but not ventral striatum of the mouse. 
5. On the role of tonic autoinhibition 
Many of the distinctions between the fast and slow DA domains of the dorsal striatum appear 
related to the status of tonic autoinhibition, which is absent in the fast domains but dominant in 
the slow domains (Moquin & Michael, 2009).  In contrast, tonic autoinhibition does not appear 
to play a similar role in the NAcc.  Raclopride, the D2 antagonist, increased the overall 
amplitude of evoked responses in the both NAcc fast and slow domains but had no effect during 
the initial 200 ms or 300 ms, respectively, of the stimuli.  Thus, in the NAcc autoinhibition is 
observed after, but not before, the onset of evoked DA release, so there is no sign of tonic 
autoinhibition even in the slow domain. 
Moreover, there is no clear evidence that D2 antagonist affects the kinetics of DA 
clearance in the NAcc (Garris et al., 1994a; Benoit-Marand et al., 2001).  There is a slight but 
non-significant tendency for raclopride to increase the linear clearance rate, but this cannot be 
taken as a sign that autoreceptors are modulating DA uptake.  At the relatively low DA 
concentrations involved in these experiments, the dopamine transporter appears to be operating 
under pseudo-first order conditions and raclopride had no noticeable impact on the overall time 
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for needed for the DA signal to return to the baseline.  So, raclopride did not affect the pseudo-
first order kinetics of DA clearance. 
E. CONCLUSION 
Our findings confirm the presence of a patchwork of DA kinetics in the NAcc but also show 
substantial differences between the NAcc domains and those of the dorsal striatum.  Diffusion 
effects are clearly evident in the various profiles, but these are due to diffusion within rather than 
between the domains.  All the profiles exhibit the features of the restricted diffusion model, the 
mechanisms of which have been explored in detail by others (Nicholson, 1995; Nicholson & 
Sykova, 1998; Sykova & Nicholson, 2008).  The various profiles are observed with the same 
FSCV technique, the same carbon fiber electrodes, and the same stimulus procedures, and so 
appear unlikely to be due to instrumental distortions. The regional and domain-dependence of the 
profiles appear, therefore, to reflect the distinct DA kinetics at the various recording locations. 
Our findings reveal two substantial differences between the NAcc and dorsal striatum.  
First, we find no clear evidence of any autoinhibitory tone in the NAcc.  Second, and likely a 
consequence of the first, there are no clear signs of short-term plasticity in the NAcc, where 
multiple consecutive stimuli evoked consistent DA release.  The functional significance of the 
patchworks themselves, the short-term plasticity in the dorsal striatum, and the lack thereof in the 
NAcc, remains to be established. 
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F. SUPPORTING INFORMATION 
 
Figure II.8 Representative microelectrode placements in the NAcc. 
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Figure II.9 Apparent Vmax of DA clearance in fast and slow domains of the NAcc and dorsal striatum. (a) Linear 
DA clearance rates measured after stimulation at varying stimulus intensities (response profiles in Figure II.3: 
stimulus = 3 s, 60 Hz, 150-550 μA) in fast (red, n = 4 rats) and slow (blue, n = 6 rats) NAcc domains.  The clearance 
rates reached a constant maximum value (apparent Vmax) at stimulus intensities ≥300 μA and ≥450 μA in fast and 
slow domains, respectively.  (b) Neither of these apparent Vmax values is significantly different from those obtained 
in the dorsal striatum using the same experimental design (independent-samples t-test, p > 0.05 in both fast and 
slow). 
  54 
 
Figure II.10 Evoked DA concentrations in fast domains at first and second 100 ms of the stimulus and 100 ms after 
the end of the stimulus at different current intensities. Average (± SEM, n = 4 rats) of the evoked DA amplitude at 
0.1-0.3 s after the start of the stimulus. The amplitude of DA release in the fast profile after the first 100 ms (blue) is 
independent of the stimulus intensity (one-way ANOVA with a repeated measures design, F(6,18) = 0.559, p > 0.5).  
The amplitude increases steadily with stimulus intensity 200 ms (red) and 300 ms (green) after the stimulus begins 
(the data shown in green correspond to overshoot). 
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Figure II.11 Overshoot in dorsal striatum and NAcc. A representative example of a fast profile recorded in the 
dorsal striatum (red) and NAcc (blue) using the same carbon fiber electrode in a single rat.  The symbols mark 
where the stimulus begins and ends.  Overshoot was observed in the NAcc but not in the dorsal striatum. 
 
Figure II.12 Time course of DA clearance in the NAcc.  The solid lines are the averages of fast (blue, n=4 rats) and 
slow (red, n=6 rats) profiles recorded at a stimulus intensity of 250 μA (left) and 550 μA (right).  The profiles are 
normalized with respect to the DA amplitude recorded at the end of each 3-s stimulus.  The dotted lines report the 
standard error of the means.  This format of presentation demonstrates that the time course of DA clearance in the 
fast and slow domains is indistinguishable. 
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Figure II.13 The placement of the stimulating electrode does not determine whether recording sites exhibit fast or 
slow profiles.  Evoked responses were recorded in the NAcc at 5-min intervals (60 Hz, 250 μA, 3-s).  The 
stimulating electrode was lowered by 100 μm between each stimulus.  The maximum DA amplitude observed in fast 
(n=3 rats) and slow (n=4 rats) domains (mean ± SEM) are plotted on the left: both the domain and the stimulus 
location were significant factors (two-way ANOVA with repeat measures design, domain factor F(1,5) = 144.572; n = 
7;  p = 0.00007, stimulus location factor F(4,20) = 10.211;  p = 0.0001).  The stimulus location was only a significant 
factor due to the lower amplitude observed when the stimulating electrode had been lowered by 400 μm from its 
original depth: this is most likely due to disruption of the MFB by the stimulating electrode.  If results from the 400-
μm location are omitted from the analysis, the stimulus location is not a significant factor.  On the right, two 
representative profiles show the essential features of the fast and slow profiles are preserved when the stimulating 
electrode is lowered through the MFB. 
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CHAPTER III.  REGION- AND DOMAIN-DEPENDENT ACTION OF 
NOMIFENSINE 
Adapted with revision from Zhan Shu, I. Mitch Taylor, Seth H. Walters and Adrian C. Michael 
(2014) European Journal of Neuroscience, 40, 2320-2328. 
A. INTRODUCTION 
Dopamine (DA) is crucial to the motor, motivation, and reward related functions of the central 
nervous system (Johnson & Kenny, 2010; Jenkinson & Brown, 2011; Volkow et al., 2011).  DA 
neurotransmission is initiated by the release of DA molecules and terminated by their reuptake 
via the dopamine transporter (DAT).  The spatiotemporal dynamics of DA’s extracellular 
concentration, and therefore the extent and duration of DA receptor stimulation, are intricately 
determined by the kinetics of DA release and clearance as well as the mass transport of DA 
through the extracellular space (Wightman et al., 1988; Garris et al., 1994; Cragg & Rice, 2004; 
Taylor et al., 2012; Taylor et al., 2013).  Because numerous drugs that affect DA release and 
clearance have therapeutic value (Gottwald & Aminoff, 2011; Volkow et al., 2012) and/or abuse 
potential (Phillips et al., 2003; Hollander & Carelli, 2007), it is highly significant to know how 
such drugs alter the spatiotemporal dynamics of DA concentrations in the extracellular space. 
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The psychostimulants cocaine and nomifensine are competitive DAT inhibitors and thus 
alter DA’s extracellular dynamics (Church et al., 1987; Koob & Bloom, 1988; Kuhar et al., 
1991).  That the actions of such drugs vary between brain regions has been a subject of intense 
interest.  For example, their tendency to preferentially increase measures of extracellular DA in 
the nucleus accumbens (NAc) compared to the dorsal striatum (DS) conforms well with the 
central importance of the NAc in the mechanisms of substance abuse (Dichiara & Imperato, 
1988; Carboni et al., 1989; Cass et al., 1992; Cass et al., 1993; Wu et al., 2001a).  But, the 
present understanding of this preferential action remains somewhat incomplete because, first, the 
DS receives the densest dopaminergic innervation in the brain (Bjorklund & Dunnett, 2007), 
second, as yet there is no clear sign that DAT inhibitors exhibit greater potency in the NAc than 
DS (Boja & Kuhar, 1989; Izenwasser et al., 1990; Jones et al., 1995b) and, third, as yet there is 
no clear sign that competitive DAT inhibitors, such as cocaine and nomifensine, preferentially 
increase the DAT’s apparent KM in the NAc: rather, prior reports suggest that nomifensine acts 
preferentially in the DS and that cocaine acts non-preferentially (Wu et al., 2001a; Wu et al., 
2001b). 
We (Shu et al., 2013) have reported that the core of the NAc (NAcc), similarly to the DS 
(Moquin & Michael, 2009; Wang et al., 2010; Moquin & Michael, 2011), contains a patchwork 
of DA kinetic domains that respond in unique fashion to electrical stimulation of the medial 
forebrain bundle.  The discovery of these domains leads us to hypothesize that the actions of 
nomifensine might be domain-dependent within the NAcc, as we previously found to be the case 
in the DS (Moquin & Michael, 2009; Taylor et al., 2012).  So, the objectives of the present study 
were, first, to test the hypothesis that nomifensine exhibits domain-dependent actions in the 
NAcc and, second, to compare nomifensine’s actions in the NAcc with those in the DS (Taylor et 
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al., 2013).  We report herein for the first time a) that, within the NAcc, nomifensine 
preferentially promotes evoked DA release in the slow compared to the fast domains and b) that 
nomifensine preferentially increases the apparent KM of DA clearance in the NAcc compared to 
the DS. 
B. MATERIALS AND METHODS 
1. Solutions, drugs, and reagents 
Chemicals were used as-received from the indicated suppliers and solutions were prepared with 
ultrapure water (NANOPure, Barnstead, Dubuque, IA, USA). Nomifensine maleate (Sigma-
Aldrich, St Louis, MO) was dissolved in phosphate buffered saline (137 mM NaCl, 2.7 mM KCl, 
1.47 mM KH2PO4, 10 mM Na2HPO4, pH 7.4).  Dopamine hydrochloride (Sigma-Aldrich) was 
dissolved just before use in artificial cerebrospinal fluid (aCSF, 144 mM NaCl, 1.2 mM CaCl2, 
2.7 mM KCl, 1.0 mM MgCl2, 2.0 mM NaH2PO4, pH 7.4) and stored under N2 to prevent DA 
oxidation. Paraformaldehyde (PFA, 4% in phosphate buffered saline) was prepared from resin 
(Sigma-Aldrich) and stored at 4 °C before use.  Isoflurane was from Baxter Healthcare 
(Deerfield, IL, USA). 
  60 
2. Carbon fiber electrodes 
Carbon fiber microelectrodes were constructed with 7-μm diameter carbon fibers (T650, Cytec 
Carbon Fibers, LLC, Piedmont, SC, USA).  The fibers were trimmed to a length of 200 μm and 
immersed in reagent grade isopropyl alcohol (Sigma) for 20 min before use (Bath et al., 2000). 
3. Fast-scan cyclic voltammetry (FSCV) 
Background subtracted fast-scan cyclic voltammetry (FSCV) was performed with a potentiostat 
(University of Pittsburgh, Department of Chemistry Electronics Shop), a current amplifier 
(Keithley 428, Keithley Instruments, Inc., Cleveland, OH, USA), and software (TarHeel CV v4, 
courtesy of Prof. Michael Heien, Department of Chemistry and Biochemistry, University of 
Arizona, Tucson, USA (Heien et al., 2003)).  Between scans the applied potential was held at 0 
V vs. Ag/AgCl.  During the scans the voltage was swept linearly to 1.0 V, then to 0.5 V and back 
to 0 V at 400 V/s: the scan repetition frequency was 10 Hz. 
4. Electrode calibration 
Electrode calibration was performed using freshly prepared DA solutions before and after in vivo 
recordings.  In vivo dopamine concentrations were determined by post-calibration. 
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5. Subjects 
Subjects were male Sprague-Dawley rats (n = 37, 250-275 g, Hilltop Laboratories, Scottsdale, 
PA, USA).  All procedures involving animals were in accordance with NIH guidelines 
(publication 86-23) and approved by The Institutional Animal Care and Use Committee of the 
University of Pittsburgh. 
6. Surgery 
Surgery was performed as described previously (Shu et al., 2013) under isoflurane anesthesia 
(5% by vol. initially and 2.5% for maintenance): isoflurane was vaporized (Cyprane Fortec, 
Fraser Harlake, Inc., Orchard Park, NY) in oxygen and delivered through a ventilator (Harvard 
Apparatus, Holliston, MA, USA).  The anesthetized rats were maintained at 37 °C with a 
homoeothermic blanket (Harvard Apparatus).  Carbon fiber electrodes were first placed into the 
striatum (A/P +1.2 mm, M/L +1.4 mm, D/V 5.0 mm below dura) (Paxinos & Watson, 1998) and 
bipolar, stainless-steel stimulating electrodes (MS303/B, Plastics One, Inc., Roanoke, VA, USA) 
were placed as described before (Ewing et al., 1983; Kuhr et al., 1984; Michael et al., 1987) in 
the medial forebrain bundle (A/P -4.3 mm, M/L +1.2 mm, D/V from 7.5 below dura: the vertical 
coordinate was adjusted until evoked release was observed).  Finally, without moving the 
stimulating electrode, the carbon fiber electrodes were slowly lowered into the NAcc (D/V 6.6-
7.6 mm below dura). 
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7. Electrical Stimulation 
Electrical stimulation (constant current, biphasic square wave, pulse intensity 250 μA, pulse 
width 2 ms) was supplied by a pair of stimulus isolators (NL800A, Digitimer, Ltd., 
Hertfordshire, England).  Stimulation was performed at 60, 30 and 15 Hz: details of the train 
duration are provided in the Results section. 
8. Histology 
Histological examination was performed as described previously (Peters et al., 2004; Shu et al., 
2013) to verify that microelectrodes were correctly placed in the NAcc. 
9. Experimental design 
Once the recording and stimulating electrodes were in position, stimulus responses were 
recorded before and 30 min after a single dose of nomifensine (20 mg/kg i.p.) with no alterations 
in the electrodes, recording location, stimulating location, stimulation parameters, etc.  As during 
our prior study in the DS (Taylor et al., 2012), we compared pre- and post-nomifensine responses 
in the same group of animals to assure the effect of the drug was established under the same 
recording and stimulating conditions. 
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10. Data analysis 
Overshoot duration was defined by the time needed after the end of the stimulus for the evoked 
response to reach its maximum amplitude.  The overshoot concentration was the amount by 
which the dopamine concentration continued to increase after the end of the stimulus.  We 
quantified the apparent KM of DA clearance by numerically evaluating the derivative of the 
descending phase of the response and finding the point at which the slope was one-half the 
corresponding apparent Vmax reported by Shu et al., 2013.  Statistical analyses were by the t-test, 
two-way analysis of variance (ANOVA) and two-way ANOVA with a repeated measures design 
(IBM SPSS Statistics 20). 
C. RESULTS 
Evoked responses reported recorded within the NAcc were objectively identified as fast or slow 
domains according to the criterion established by Shu et al., 2013 (see Figure II.1 of Chapter II: 
fast sites produce evoked DA within 200 ms of the start of a stimulus (60 Hz, 250 μA) but slow 
sites do not).  The fast and slow profiles recorded during this study exhibit no statistically 
significant differences from those recorded in different animals and reported in Figure II.2 of 
Chapter II (Supplementary Information, Figure III.10).  The sites of all NAcc recordings reported 
herein were confirmed by histology (Supplementary Information, Figure III.11). 
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1. Format of the presentation of evoked responses 
Evoked responses are reported in Figures III.1-4, Figure III.6, and Supplementary Figures III.10 
and III.12 in a consistent format (Figure III.7 is in a different format, which is explained below).  
The solid and dash lines are the averages of responses recorded in groups of rats: the n values, 
the number of rats per group, are stated in the figure legends.  In the main text, solid lines are 
pre-nomifensine responses from fast and slow domains, and dash lines are post-nomifensine 
responses: the dotted lines are the ±SEM intervals: black symbols denote when the stimulus 
begins and ends.  The stimulus frequency and duration are stated in the text and in the figure 
legends: the stimulus current was fixed at 250 μA. 
2. Domain-dependent effects of nomifensine: fast domains 
Nomifensine affects evoked responses in the NAcc fast domains (Figure III.1, stimulus = 0.2 s, 
60 Hz: Figure III.2, stimulus = 1 s, 60 Hz).  Nomifensine did not significantly affect the response 
during the 0.2-s stimulus (Figure III.1b, two-way ANOVA, repeated measures design: 
nomifensine F(1,12) = 0.220, p > 0.5) but significantly increased both the duration (Figure III.1c, 
paired-samples t-test: p < 0.00005) and amplitude (Figure III.1d, paired-samples t-test: p < 
0.005) of the overshoot.  Nomifensine did not affect the response during the 1-s stimulus (Figure 
III.2b, time 0.1 to 1.0 s, two-way ANOVA, repeated measures design: nomifensine F(1,12) = 
2.190, p > 0.1) but significantly increased both the duration (Figure III.2c, paired-samples t-test: 
p < 0.0005) and amplitude (Figure III.2d paired-samples t-test: p < 0.005) of the overshoot.  
Thus, in the NAcc fast domains, nomifensine primarily acts on the overshoot portion of the 
response to brief stimuli. 
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Figure III.1 The effects of nomifensine on evoked DA overflow in fast NAcc domains (stimulus = 0.2 s, 60 Hz, 250 
μA).  In this and subsequent figures, solid and dash lines show the average of responses recorded in a group of rats 
and dotted lines show the SEM.  Black symbols denote when the stimulus starts and stops. (A) Evoked responses (n 
= 7) recorded before (solid) and after (dash) nomifensine administration. (B) Nomifensine did not significantly (two-
way ANOVA, repeated measures design: nomifensine F(1,12) = 0.220, p > 0.5) affect the DA overflow during the 0.2 
s stimulus. (C & D) Nomifensine significantly increased the duration and amplitude (paired-samples t-tests: **p < 
0.005, **** p < 0.00005) of the stimulus overshoot. 
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Figure III.2 The effects of nomifensine on evoked DA overflow in fast NAcc domains (stimulus = 1 s, 60 Hz, 250 
μA). (A) Evoked responses (n = 7) recorded before (solid) and after (dash) nomifensine administration. (B) 
Nomifensine did not significantly (time 0.1 to 1.0 s, two-way ANOVA, repeated measures design: nomifensine 
F(1,12) = 2.190, p > 0.1) affect the rate of evoked DA overflow during the stimulus. (C & D) Nomifensine 
significantly increased the duration and amplitude (paired-samples t-tests: **p < 0.005, ***p < 0.0005) of the 
stimulus overshoot. 
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3. Domain-dependent effects of nomifensine: slow domains 
Nomifensine affects evoked responses in the NAcc slow domains (Figure III.3, stimulus = 0.2 s, 
60 Hz; Figure III.4, stimulus = 1 s, 60 Hz).  Before nomifensine, the 0.2-s stimulus evoked no 
detectable DA overflow.  However, after nomifensine the response exhibited a maximal 
overflow of ~1 μM DA and a duration of ~10 s.  The onset of these responses was delayed with 
respect to the start of the stimulus: in four out of eight cases, the onset of the overflow began 
after the end of the stimulus.  Nomifensine significantly increased the responses during the 1 s 
stimulus (Figure III.4b, time 0.1 to 1.0 s, two-way ANOVA, repeated measures design: 
nomifensine F(1,14) = 6.738,  p < 0.05; time & nomifensine interaction F(9,126) = 8.451, p < 0.01) 
and significantly increased both the duration (Figure III.4c, paired-samples t-test: p < 0.0005) 
and amplitude (Figure III.4d, paired-samples t-test: p < 0.005) of the response overshoot.  Thus, 
nomifensine acts on both DA release during the stimulus and the overshoot of the response in 
NAcc slow domains. 
 
Figure III.3 Evoked responses (n = 8) recorded in slow NAcc domains (stimulus = 0.2 s, 60 Hz, 250 μA) before 
(solid) and after (dash) nomifensine administration. 
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Figure III.4 Effect of nomifensine on evoked DA overflow in slow NAcc domains (stimulus = 1 s, 60 Hz, 250 μA).  
(A) Evoked responses (n = 8) recorded before (solid) and after (dash) nomifensine administration. (B) Nomifensine 
significantly (time 0.1 to 1.0 s, Θ two-way ANOVA, repeated measures design: nomifensine F(1,14) = 6.738,  p < 
0.05; time & nomifensine interaction F(9,126) = 8.451, p < 0.01) increased the rate of DA overflow during the 
stimulus. (C & D) Nomifensine significantly increased the duration and amplitude (paired-samples t-tests: **p < 
0.005, ***p < 0.0005) of the stimulus overshoot. 
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4. Domain-dependent effects of nomifensine: fast and slow comparisons 
Within the NAcc, nomifensine preferentially increased three measures of evoked DA release in 
the slow compared to the fast domains (Figure III.5: the post-nomifensine values of initial rate of 
DA release and the duration and amplitude of the overshoot are normalized with respect to their 
pre-nomifensine values).  Nomifensine preferentially increased the initial rate of DA release and 
the duration and amplitude of the overshoot in the slow (Figure III.5, blue bars) compared to the 
fast domains (Figure III.5, red bars) (Figure III.5a-c, independent-samples t-test: p < 0.05). Thus, 
nomifensine preferentially enhances evoked DA release in the slow NAcc domains. 
5. The effects of nomifensine in slow domains during low frequency stimulations 
We examined the effect of nomifensine on evoked responses in NAcc slow domains at lower 
stimulus frequency (Figure III.6).  Upon stimulation at 15 Hz, a response was observed only after 
nomifensine administration (Figure III.6a).  Hence, the NAcc slow domain exhibits the same 
“timing mismatch” phenomenon that we described previously in the slow domains of the DS 
(Taylor et al., 2013).  Upon stimulation at 30 Hz, the pre-nomifensine response exhibited an 
initial delay of 1-2 s followed by short-term facilitation of evoked release, i.e. the response 
curved-upward as the stimulation continued (Figure III.6b, solid).  Nomifensine eliminated the 
initial delay and the short-term facilitation but also increased the duration of the overshoot 
(Figure III.6b, dash). Thus, nomifensine exhibits an asymmetric effect on the temporal features 
of the DA response: nomifensine decreases the initial delay in the response when the stimulus 
begins but increases the overshoot when the stimulus ends. 
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Figure III.5 The normalized effects of nomifensine on the evoked NAcc responses are domain-dependent (stimulus 
= 1 s, 60 Hz, 250 μA). (A) The initial rate of DA overflow (fast: 0-0.3s, slow: 0.3-0.5s), (B) the overshoot duration, 
and (C) the overshoot amplitude are reported here normalized with respect to their pre-nomifensine values. (A-C) 
Nomifensine preferentially increased the initial rate of DA release and the duration and amplitude of the overshoot 
in the slow (blue bars) compared to the fast domains (red bars) (independent-samples t-tests: *p < 0.05). 
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Figure III.6 Evoked responses (n = 5) recorded in NAcc slow domains before (solid) and after (dash) nomifensine 
administration (A, stimulus = 180 pulses, 15 Hz, 250 μA: B, stimulus = 180 pulses, 30 Hz, 250 μA). 
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6. Comparison of DA’s NAcc dynamics after nomifensine: 0.2 s responses 
It is relevant (see Discussion) to compare the dynamics of the post-nomifensine fast and slow 
responses (Figure III.7).  Figure III.7 compares the 0.2 s slow post-nomifensine response (dash) 
to the 0.2 s fast post-nomifensine response after subtraction of the fast pre-nomifensine response 
(solid), both normalized to their respective maximum amplitude.  The intention of subtracting the 
fast pre-response from the fast-post response is to isolate the nomifensine-induced overshoot 
component: this subtraction was not necessary in the case of the slow response because the pre-
response was non-detectable.  The nomifensine-induced overshoots observed in fast and slow 
domains are essentially identical (Figure III.7). 
 
Figure III.7 Comparison of “pure overshoots” observed in fast (solid) and slow (dash) NAcc domains after 
nomifensine administration (stimulus = 0.2 s, 60 Hz, 250 μA). The blue line was obtained from Figure III.1a by 
subtracting the pre-drug response from the post-nomifensine response (see also Figure 9 of Taylor et al., 2012).  The 
dash line is from Figure III.3.  The two responses are normalized to their maximum amplitudes to enable 
comparison of their temporal features (SEMs omitted for clarity). 
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7. Nomifensine’s impact on the apparent KM of the DAT 
We quantified the apparent KM of DA clearance by numerically evaluating the derivative of the 
descending phase of the responses.  For this purpose, we found it necessary to extend the 
stimulus duration to 3 s to ensure that the rate of clearance exceeded the one-half Vmax values 
(see Supplementary Information: the 3-s responses are reported in Figure III.12 and the 
individual apparent KM values are reported in Figure III.13).  To gauge the effects of 
nomifensine, we normalized the post-nomifensine apparent KM values with respect to their pre-
nomifensine magnitude (Figure III.8).   Nomifensine significantly increased all four apparent KM 
values.  The increase in apparent KM was significantly larger in the NAcc (~500%) than in the 
DS (~200%) but was not domain-dependent (two-way ANOVA: regions F(1,20) = 13.213, p < 
0.002, domains F(1,20) = 0.932, p > 0.3).  To our knowledge, this is the first report of a 
preferential kinetic action of a DAT inhibitor in the NAcc compared to the DS. 
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Figure III.8 Comparison of apparent KM values obtained in fast and slow domains in the NAcc (red) and DS (blue).  
The post-nomifensine apparent KM values are normalized with respect to the pre-drug values.  The normalized 
values are region-dependent and domain-independent († two-way ANOVA: regions F(1,20) = 13.213, p < 0.002; 
domains F(1,20) = 0.932, p > 0.3). 
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8. Color plots 
In order to acquiesce to the demands of two reviewers of this report, we provide 3-dimensional 
color plots of the FSCV data for the 1-s stimulus responses recorded before and after 
administration of nomifensine in the fast domains of the NAcc in Figure III.9 (more color plots 
see Supporting Information Figure III.14).  These color plots, which provide no additional 
information over that which has already been stated above, show the FSCV data in a voltage-
versus-time coordinate with current represented by a color scale.  To prepare these plots, we 
normalized the background-subtracted FSCV currents with respect to each electrode’s post-
calibration sensitivity factor and averaged the results across the group of animals (n = 7).  The 
plots show the dopamine oxidation peak, the quinone reduction peak, and background noise. 
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Figure III.9 Color plot (see text for explanation) of the FSCV data recorded during a 1-s stimulus (A) before and 
(B) after administration of nomifensine in fast NAcc domains. 
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D. DISCUSSION 
The domain-dependent evoked DA responses (pre-nomifensine) recorded in the NAcc are not 
statistically different from those reported previously by Shu et al. (2013, see Supplementary 
Figure III.10), confirming that the NAcc domains are preserved across groups of animals.  As in 
the DS (Taylor et al., 2012), nomifensine exerts robust and domain-dependent actions on evoked 
responses in the NAcc (Figures III.1-6).  Together with our previous DS results (Taylor et al., 
2012), the present study provides a comprehensive evaluation of both the region-dependent and 
domain-dependent actions of a DAT inhibitor, for the first time. 
1. Summary of nomifensine’s actions in the NAcc 
When stimulation is delivered at 60 Hz in relatively brief trains (0.2 or 1 s, Figures III.1-4), 
nomifensine increases both the duration and amplitude of the response overshoot in both 
domains.  In the case of the 0.2 s stimulus trains, the post-nomifensine maximum DA signal in 
the fast domain was more than 400% of the pre-nomifensine maximum amplitude and the 
overshoot duration was ~500% longer than the stimulus.  In the slow domain, the pre-
nomifensine response to the 0.2 s stimulus train was non-detectable (Figure III.3), so the post-
nomifensine response is predominantly overshoot.  Interestingly, the temporal features of the 
overshoots in the fast and slow domains are essentially identical (Figure III.7).  Nomifensine 
significantly increased the DA concentrations observed during the 1-s stimulus trains in the slow 
domains, but not in the fast domains. 
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2. Nomifensine preferentially acts on NAcc slow domains compared to fast domains 
With a 1-s stimulus, it was possible to quantify the initial rate of evoked DA release as well as 
the duration and amplitude of the overshoots in fast and slow domains under consistent 
experimental conditions.  We normalized the post-nomifensine values with respect to their pre-
nomifensine values (Figure III.5).  All three measures of evoked DA release were significantly 
larger in the slow domain.  We therefore conclude that nomifensine acts preferentially on evoked 
DA release in the NAcc slow domains compared to the NAcc fast domains.  We report this 
phenomenon here for the first time. 
Taylor et al. (2012) reported the domain-dependent actions of nomifensine on evoked DA 
release in the DS.  There are notable differences between the NAcc and DS.  First, nomifensine 
had a much larger effect on the initial rate of DA release in the DS slow domains (~800%) than 
the NAcc slow domains (~200%).  In contrast with the NAcc, nomifensine’s actions on the 
duration and amplitude of the DS overshoot were largest in the fast domains.  Thus, we report 
here for the first time that the domain-dependent actions of nomifensine are also region-
dependent.  These findings add to the view that the domains of the NAcc and DS are truly 
distinct from one other, reinforcing the concept that DA kinetics are both region and domain 
dependent. 
3. Nomifensine’s actions on the apparent KM of DA uptake: considerations 
As a competitive DAT inhibitor, nomifensine’s primary pharmacological action is to change the 
apparent KM of DA uptake.  However, DAT inhibitors have additional secondary actions.  For 
example, in anesthetized animals, DAT inhibition decreases the firing rate of DA neurons via 
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indirect agonism of the D2 receptors (Studer & Schultz, 1987; Einhorn et al., 1988; Mercuri et 
al., 1991), while in non-anesthetized animals DAT inhibitors induce phasic DA events (Aragona 
et al., 2008) and burst firing of DA neurons (Koulchitsky et al., 2012).  Here, however, we wish 
to evaluate nomifensine’s primary action by determining the apparent KM of DA clearance.  To 
do so, however, requires consideration of how to go about extracting apparent KM information 
from evoked responses. 
In several previous reports, KM values were quantified by means of a numerical model 
that simulates the evoked responses (Wightman et al., 1988; Jones et al., 1995a; Wu et al., 
2001a; Wu et al., 2001b).  The model assumes that a gap, or a physical space, is interposed 
between the recording electrode and nearby DA terminals: such a gap is expected to cause 
diffusional distortion of the evoked responses.  However, as we have explained before (Moquin 
& Michael, 2009; Taylor et al., 2012), the observed features of evoked responses in the DS cast 
doubt on the diffusion gap distortion model, which in turn, casts doubt on the kinetic values 
obtained via simulation.  We now report that the same issue arises in the NAcc. 
A diffusion gap is predicted to cause two types of temporal distortion of the evoked 
responses; an initial lag in the DA signal when the stimulus begins and an overshoot of the DA 
signal after the stimulus ends.  A diffusion gap would necessarily cause these distortions to go 
hand-in-hand: if there is an initial lag, there must also be an overshoot, and vice versa.  However, 
in both the DS and NAcc, responses with overshoot but without initial lag are entirely 
commonplace.  In fast domains, for example, DAT inhibition leads to prominent overshoot but 
no obvious lag.  According to the diffusion gap model, this should not be. 
A modified diffusion gap model described by Venton et al., (2003) hypothesized that 
DAT inhibition increases the apparent dimension of the diffusion gap, invoking the concept that 
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DAT inhibition extends DA’s lifetime in the extracellular space and so enables it to diffuse 
further.  The evoked responses do not support this hypothesis: 
First, both in the DS and the NAcc, DAT inhibition diminishes the initial lag in slow 
domains, this effect being most obvious at low stimulus frequencies (Figure III.6; see also Figure 
5 of Taylor et al., 2013).  This observation directly contradicts the hypothesis that DAT 
inhibition increases the apparent diffusion gap.  Moreover, the rapid onset of the post-
nomifensine responses confirms the presence of DA terminals in close proximity to the recording 
electrode, which shows that there is no diffusion gap to cause diffusional distortion.  Rather than 
diffusional distortion, we conclude that the temporal features of the evoked responses reflect the 
local activity of DA terminals in the immediate vicinity of the recording site. 
Second, our findings do not provide clear evidence that DA’s diffusion distance post-
nomifensine is domain dependent (Figure III.7).  Originally, responses with prominent initial lag 
were attributed to a poor choice of recording site with a large diffusion gap interposed between 
the electrode and its nearest-neighbor DA terminals (Kuhr et al., 1987; Engstrom et al., 1988; 
Wightman et al., 1988).  Likewise, responses without lag were attributed to small gaps and 
minimal diffusional distortion.  In that case, however, then the different gap sizes would 
necessarily produce distinct temporal profiles, regardless of experimental conditions.  After 
nomifensine, however, this is simply not what is observed (see Figure III.7, above, and Figure 9 
of Taylor et al., 2012): the essentially identical appearance of the post-nomifensine overshoots 
would be impossible if the fast and slow responses were caused by different gaps. 
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4. Nomifensine’s actions on the apparent KM of DA uptake: the analysis 
Because our findings do not confirm the presence of a diffusion gap, we chose to quantify 
apparent KM directly from the slope of the descending phase of the response.  The advantage of 
slope analysis is that makes no mass transfer assumptions.  However, the kinetic parameters 
obtained by slope analysis are clearly not the intrinsic, biophysical parameters of the DAT per se.  
Nevertheless, if it is to be assumed, as is generally the case, that the DA signal at the electrode is 
a useful analog of DA neurotransmission, then the apparent values are of great interest for the 
clear, simple, and logical reason that mass transport delivers DA molecules not only to the 
recording electrodes but also to their pre- and post-synaptic targets. 
Nomifensine significantly increases the apparent KM in both the fast and slow domains of 
both the NAcc and DS: this is an expected result because nomifensine is a competitive inhibitor.   
However, nomifensine preferentially increases the apparent KM in the NAcc compared to the DS 
(Figure III.8), a phenomenon we report here for the first time.  Interestingly, although the effect 
of nomifensine on apparent KM is clearly region-dependent, it is not domain-dependent: the 
proportional increase in apparent KM was similar in the fast and slow domains of each region 
(Figure III.8).  Thus, the change in apparent KM may not by itself explain all the region and 
domain dependent actions of nomifensine on DA release.  But, as mentioned above, DAT 
inhibitors have secondary pharmacological effects. 
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E. CONCLUSION 
This study reaffirms the presence of a patchwork of DA kinetic domains within the NAcc and 
establishes that nomifensine’s actions within the NAcc are domain dependent.  Nomifensine 
preferentially enhances three measures of DA release in the NAcc slow domains compared to the 
NAcc fast domains: the rate of initial release as well as the duration and amplitude of the 
overshoot. In this respect, the domain-dependent actions of nomifensine are distinct from those 
in the DS.  Moreover, nomifensine preferentially increases the apparent KM of DA clearance in 
the NAcc compared to the DS, and this preferential effect was domain-independent.  This first 
report of a preferential kinetic effect of a DAT inhibitor in the NAcc is in good accord with prior 
literature showing that DAT inhibitors preferentially affect the NAc compared to the DS. 
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F. SUPPORTING INFORMATION 
 
Figure III.10 The domain-dependent evoked DA responses are consistent across animals. Evoked DA responses 
recorded in the present group of subjects (solid lines) are not significantly different from those we reported 
previously (dash lines with black dots as SEM, Figure II.2 in Chapter II) in both fast (two-way ANOVA with a 
repeated measures design from 0.1 to 2.9s, p > 0.3) and slow (two-way ANOVA with a repeated measures design 
from 0.1 to 2.9s, p > 0.5) domains.  The recording locations were objectively identified as corresponding to fast or 
slow domains on the basis of the amplitude of evoked DA release during the first 200 ms of the stimulus, as 
thoroughly explained in Chapter II. 
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Figure III.11 Representative microelectrode placements in the NAcc. One representative electrical lesion (arrow) 
on the brain slice is enlarged on the right side. Scale bar: 250 μm. 
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Figure III.12 Slope analysis to extract apparent KM values.  (A&B) Pre- and post-nomifensine responses recorded 
in fast domains (average ± SEM, NAcc n = 7, DS n = 6) and (C&D) slow domains (average ± SEM, NAcc n = 7, DS 
n = 8) in the NAcc (red) and DS (blue) (stimulus = 3 s, 60 Hz, 250 μA). The black circles indicate the average 
apparent KM values of DA clearance (see details in Figure III.13, Discussion and Figure III.8). 
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Figure III.13 Comparison of apparent KM values obtained in fast and slow domains in the NAcc (red) and DS 
(blue). Apparent KM values of DA clearance are measured from the responses in Figure III.12 and reported as the 
average ± SEM. (A) In the pre-drug condition, the apparent KM of DA clearance is domain- but not region-
dependent ( two-way ANOVA domains F(1,20) = 16.257, p < 0.001, regions F(1,20) = 2.276, p > 0.14). (B) Post-
nomifensine, the apparent KM of DA clearance is domain- and region-dependent (§ two-way ANOVA domains 
F(1,20) = 18.989, p < 0.0005, regions F(1,20) = 18.606, p < 0.0005). 
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Figure III.14 3-dimensional color plots of the FSCV data. To prepare these plots, we normalized the background-
subtracted FSCV currents collected before (left) and after (right) the administration of nomifensine with respect to 
each electrode’s post-calibration sensitivity factor and averaged the results across the group of animals (Fast: n=7, 
Slow: n=8). 
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